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Although the relationship between elevated blood cholesterol 
levels and increased incidence of coronary heart disease 
(CHD) has been recognized for many years, concerted efforts 
to identify and treat individuals with hypercholesterolemia 
have emerged recently. In recent years evidence has 
accumulated to indicate that cholesterol plays a major role 
in the development of atherosclerotic coronary disease. 
Various factors linking cholesterol to atherosclerosis have 
been reviewed (Roberts, 1988) which provide evidence that 
elevation of total blood cholesterol (specifically 
LDL-cholesterol) is the cause for the development of 
atherosclerosis. These include: 
(1) Feeding high cholesterol diets to certain nonhuman 
animals produces atherosclerotic plaques similar to 
those OGCuring in humans. 
(2) Cholesterol is found in both experimentally induced 
atherosclerotic plaques in nonhuman animals and in 
plaques in human. 
(3) Atherosclerotic plaques, large enough to produce 
clinical probloms, occur only in porsona havin/? planrna 
total cholesterol levels > 150 mg/dl for long periods 
of time. 
(4) The higher the blood total cholesterol level the 
greater the chance of having symptomatic and fatal 
atherosclerotic disease. 
(5) The higher, the serum -total and LDL-cholesterol levels, 
the greater the extent of the atherosclerotic plaques. 
(6) Lowering the blood total cholesterol and LDL-cholester-
ol levels decreases the chance of fatal or nonfatal 
atherosclerotic disease. 
(7) Atherosclerotic plaques regress when high blood 
cholesterol levels are lowered. 
Moreover, hyperlipoproteinemia, abnormal platelet function 
(thrombosis) and macrophage uptake of modified lipoproteins 
contribute to the progression of the atherosclerotic process. 
Therapeutic agents which interfere or reverse one or more 
of these pathological processes should reduce clinical 
manifestations in the form of myocardial infarction, 
ischaeraia, variant angina and thromboembolic disorders 
(HiluiaJs. <?t al, 1988). Hence, atherosclerosis is generally 
considered to be multifactorial disease, as such, the 
prevention or cure of the disease may be approached at 
different levels, control of plasma cholesterol and or 
atherogenic lipoproteins (VLDL and LDL) being an impoz-tant 
one. Excessive plasma VLDL and LDL are generally implicated 
as at least one of the causative factors in this major 
disease problem. 
Evidence that treatment of hypercholesterolemia reduces the 
incidence of primary CHD was first presented in 1984, witli 
publication of the results of the LRC-CPPT (Ujaid. Eaae^rcJi 
CllniG3 FroKram. 1984 a. b) . For every 1% reduction in 
cholesterol level, there was approximately a 2% reduction in 
GHD risk in participants of these studies. 
At present physicians are frequently reluctant to prescribe 
cholesterol lowering agents for a number of very good 
reasons. The bile acid sequestrants and nicotinic acid 
frequently cause side effects. Gastrointestinal problems 
such as nausea, bloating, constipation and flatulence are 
the most frequent side effects of cholestyramine and 
colestipol. Flushing occurs in most patients who receive the 
high doses of nicotinic acid that are required to reduce 
blood cholesterol levels. Poor adherence to treatment has 
also been a problem in LRC-CPPT with cholestyramine and with 
nicotinic acid in Coronary Drug Project ( Xhe. Coronary Unig. 
Fro.lect Research Group. 1975). In addition, treatment of 
hypercholesterolemia with a bile acid sequestrant is quite 
costly. Thus, there is a great need for more effective and 
better-tolerated cholesterol lowering drugs. 
Recently, clinical trials testing the safety and efficacy of 
a new class of lipid lowering drugs, which are competitive 
inhibitors of the enzyme HMG-CoA reductase, have been 
reported (tkii <?t ai,l986; Nakaya et al, 1986; Grundy and 
Vega. 1985). This enzyme catalyzes the rate limiting step in 
endogenous cholesterol synthesis in liver. Available 
informations suggest that the HMG-CoA reductase inhibitors 
are well tolerated and quite effective in reducing elevated 
total and particularly LDL-choleaterol levels. 
In the future, data from treatment trials may provide 
clearer guidelines for use of an HMG-CoA reductase inhibitor 
to manage hypercholesterolemia. 
A. ATHEROSCLEROSIS A N D LIPOPROTEINS 
To describe the mechanism of action of HMG-CoA reductase 
Inhibitors, it is necessary to understand the mechanism of 
lipid and lipoprotein metabolism. Fat absorbed from the diet 
and lipids synthesized by the liver and adipose tissue must 
be transported between various tissues and organs for 
utilization and storage. Since lipids are insoluble in water", 
the problem of their transport in an aqueous environment, 
the blood plasma, is solved by associating nonpolar lipids 
(triglycerides & cholesteryl ester) with amphipathic lipids 
(phospholipids and cholesterol) to proteins to make water 
miscible macromolecular complexes. These complexes are known 
as lipoproteins. Abnormalities of lipid metabolism occur at 
the sites of production or utilization of lipoproteins, 
causing various kinds of hypo- or hyper-lipoproteinemias.The 
most common of these is diabetes mellitus, where insulin 
deficiency causes excessive mobilization of B'FA and under-
utilization of chylomicrons and VLDL, leading to hypei-tri-
glycerideraia. Most other pathologic conditions, affecting 
lipid transport primarily, are due to inherited defects in 
synthesis of the apoprotein portion of the lipoprotein, of 
key enzymes or of lipoprotein receptors. Some of these 
defects cause hypercholesterolemia and premature athero-
sclerosis . 
Four major groups of lipoproteins have been identified that 
are important physiologically as well as in clinical 
diagnosis. These are, (i) chylomicrons, derived from 
intestinal absorption of triglycerides; (ii) VLDL derived 
from the liver for the export of triglycerides; (iii) LDL 
representing a final stage in the catabolism of VLDL; and 
(iv) HDL involved in VLDL and chylomicron metabolism and 
also in cholesterol metabolism. 
Except for LDL which is thought to be primarily the end 
product of VLDL lipolysis fShaefer &t a.1, 1978), the lipopr-
oteins are formed either by the intestinal mucosal cells 
(enterocytes) or by the liver cells (hepatocytes). The major 
lipoprotein of the intestinal origin is the chylomicron, 
however, both VLDL and HDL may also be produced by the 
intestine (iiu and Windmueller. 1978).In the gut, dietary fat 
is hydrolyaed to monoglyceride and free fatty acids which 
are then transported by an energy independent process 
into the enterocytes. Triglycerides are reformed in the 
smooth endoplasmic reticulum and packaged alongwith other 
lipids and proteins by the golgi apparatus into large 
triglyceride rich chylomicrons. The chylomicrons are 
expelled from the golgi apparatus through exocytosis into 
the intercellular space at the basal aspect of the cell 
fSabeain and Erase. 1977). The chylomicron reach the 
lymphatic system and eventually enter the blood stream 
through the thoracic duct. In the circulation 75-80% of the 
chylomicron triglyceride is hydrolyzed by the enzyme 
lipoprotein lipase (Cha.iek and Eisenberg, 1978) present in 
the vascular endothelium. As a result of hydrolysis, the 
free fatty acids are liberated and taken up into the tissue, 
esterified, stored and oxidized for future energy needs. 
After the hydrolysis of chylomicrons, monoglyceride as well 
as excess surface components are also removed from the 
chylomicrons fEisenberg and Lew. 1975) leaving cholesterol 
eater rich triglyceride poor remnant particles which bind 
with high affinity to receptors in the liver (Sherrill and 
Dietschv. 1978; Cooper and lii, 1978). The transport of 
exogenous triglyceride in this manner via chylomicrons is 
highly efficient so that cyclomicronemia ensues within few 
hours after fatty meal. This process can account for the 
transport of as much as several hundred grams of trigly-
cerides daily. In either genetic or acquired deficiency of 
lipoprotein lipase the capacity to transport triglycerides 
is quite limited and chylomicronemia may persist from meal 
to meal. This condition is also termed as exogenous hyper-
lipidemia. 
The remaining three lipoprotein classes are of endogenous 
origin. In the fasting state majority of plasma trigly-
cerides are contained in the triglyceride rich VLDL and 
hypertriglyceridemia, often but not always, means an 
increase of VLDL, sometimes also associated with an increase 
of both HDL- and LDL- triglycerides. VLDL and HDL are the 
primary contributions of liver to circulating lipoproteins. 
VLDL is secreted from the liver in much the same way as the 
chylomicrons are formed by the intestine (Qlauman, et at, 
1975). Nascent HDL formed by liver is much different from 
its circulating counterpart, however, cholesterol and 
triglyceride content of nascent VLDL is same as that of 
plasma VLDL (Mghlev- 1978). Several evidence indicate that 
the surface of the nascent lipoproteins is modified once 
they enter the extracellular environment. The metabolism of 
VLDL and production of LDL has been shown in Fig. 1. The 
cholesterol content on the surface also increases while that 
of phospholipid falls (Hamilton. 1973). Hepatogenous VLDL 
acquires C-apoproteins (apoC) from HDL when comes in the 
circulation. The apoC increases the affinity of the particle 
for lipoprotein lipase and enhances the catalytic rate of 
the enzyme on component triglycerides f Fielding. 1973; 
Nilsson-Ehle. 1980). The hydrolysis of triglyceride core 
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of VLDL normally occurs rapidly at the surface of blood 
capillaries in several tissues (most notably adipose tissue 
and heart) where most of the triglyceride fatty acid .is 
taken up into the tissues for storage or oxidation. The 
partially degraded particles (remnants) contain only a frac-
tion of triglycerides, phospholipids and apoC, originally 
present, but they retain all of the cholesterol esters and 
apoB and the bulk of cholesterol . The liver accounts for 
removal of almost all the remnant cholesterol ester and 
cholesterol. Upon hydrolysis of VLDL, surface components 
including cholesterol are released in proportion to 
triglyceride hydrolysis.Extensive hydrolysis of triglyceride 
produces the smaller and denser LDL particles. Also, during 
VLDL hydrolysis in xjixfo, the surface components (apoprotein, 
phospholipid, unesterified cholesterol) are transferred to 
HDL (Shell GL al , 1977), preserving the basic structure of 
the lipoprotein (Fig. 2 ) . Most LDL appears to be formed fi'ora 
VLDL, but there is evidence for some production dii'ectly by 
the liver (tkLfiJL and Rubinstein. 1974; Thompson and Uy^aLL, 
1976) . 
Since cholesterol esters and cholesterol are major 
components of atherosclerotic lesions, the interaction of 
the cholesterol carrying lipoproteins in plasma with the 
cells of the arterial wall seems to be important. An 
increased level of cholesterol carrying lipoprotein, LDL, is 
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aaaociat-ed with an increased risk of developing atheroscler-
otic cardiovascular disease. As LDL level increases more LDL 
presumably filters into subintimal regions and the 
cholesterol carried in LDL accumulates within the arterial 
wall (ififia «t al, 1985). 
The contribution of LDL to atherosclerosis, however, may not 
be determined solely by plasma LDL concentrations. The 
disturbances i n metabolism of LDL may also affect the 
atherogenecity of this lipoprotein. For example, it has been 
proposed that normal LDL must be modified before it can 
induce the development of foam cells (Brown and Goldstein, 
1983). Other metabolic abnormalities may also render LDL 
more atherogenic. There are several reports of such 
abnormalities rSniderman et ctl , 1980; Rrunzell et CLI , 1983; 
Teng «t ctl, 1983; ififia and Grundv, 1984). It has been shown 
that the cholesterol of atherosclerotic plSiques is derived 
from LDL particles that circulate in the blood stream. The 
more LDL there is in the blood, the more rapidly atliero-
sclerosis develops (Goldstein and Brown, 1984a). 
There is also considerable evidence that elevated level of 
plasma triglycerides is also a risk factor fox- ischaemic 
heart disease. Since LDL and VLDL both are considered to be 
atherogenic, it seems desirable to develop therapeutic 
agents which specifically lower these atherogenic 
lipoproteins. The removal of HDL from the circulation seems 
i2 
to be accomplished primarily by the liver (Rachmilewitr: et 
CLI , 1972). Therefore, cholesteryl ester carried by HDL or in 
remnants of triglyceride rich lipoproteins is transported 
to the liver where cholesterol, released on hydrolysis, is 
mainly converted to bile acids and thus excreted from the 
body. The cholesteryl ester that enters LDL, either from 
catabolism of VLDL or by transfer from HDL, may have a 
different fate. LDL serve to supply cholesterol to the 
metabolic needs of the cells, accomplished by the receptoz-
mediated endocytosis of LDL particles. The work of Exown and 
Goldstein (1977, 1979, 1983) on the cellular metabolism of 
LDL elucidated the"LDL pathway". The high affinity receptors 
bind LDL particles and extract them from the fluid that 
bathes the cells. The LDL is taken into the cells, rapidly 
followed by hydrolysis of the lipoprotein, yielding its 
cholesterol for cellular needs. In supplying cells with 
cholesterol, the receptors perform a second physiological 
function which is critical to the development of 
atherosclerosis; they remove LDL from blood stream. The 
number of receptoz's displayed on the surface of cells varies 
with the cellular demand for cholesterol. When the need is 
low,cells make fewer receptors and take up LDL at a i-educed 
rate. This protects cells against excess cholesterol but at 
a higher price, the reduction in the number of receptors 
decreases the rate of removal of LDL from the circulation. 
13 
blood level of LDL rises and atherosclerosis is accelerated. 
In WHHL rabbits, with a genetic deficiency of LDL receptor 
function, extremely high plasma LDL-cholesterol levels are 
observed with the development of atherosclerosis early in 
life (Qqldstein et al, 1983). LDL receptor activity is under 
metabolic regulation tn, vixjo, such that receptor nctivlty 
can be increased or decreased by appropriate intex-ventions 
with diet and/or drugs (Mahley and Innerarity, 1983; Bxami 
and Goldstein. 1983). 
Stimulation of receptor activity irx vivo has been reported 
in rabbits (Slater et al, 1980) and in patients with 
heterozygous FH (^h^pherd <st a.1, 1980) after cholestyramine 
treatment. Kovanen et aL, (1981) first demonstrated the 
stimulation of hepatic LDL receptor activity, by 
pharmacologic manipulation using mevinolin to treat Beagle 
dogs and later on same observations were made in FH 
heterozygotes fBilhejmer &t al, 1983). Therefore, as shown 
in Fig. 3, Bilhelmer (1984) proposed a rationale for the use 
of an inhibitor of HMG-CoA reductase alone or in combination 
with bile acid depletion to stimulate increased hepatic LDL 
receptor expression and thus to lower plasma LDL levels.This 
central metabolic position of LDL receptors particularly in 
the liver has changed the focus for therapeutic lowering of 
plasma LDL-cholesterol. When the cells of the liver have a 
high demand for cholesterol they prbduce high level of ra-RNA 
i4 
Fig. 3 RationaL& for- tho tAse o/ HHG-CoA reductase 
inhibitor alone or in comJbinatiori with. 
biL& acid, depletion to stimulate receptor 
expression and to lower plasma LDL lex>els 
[Bllhelmer (1984)] 
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for rocept.ors. Tho opposit.© phenomonon taken place whoti 
excess cholesterol accumulates in cells (Russel <et at, 
1983). The hapatic demand for cholesterol leading to 
increased expression of LDL receptors can therefore be 
achieved by inhibiting the intestinal absorption of bile 
acids and the synthesis of cholesterol. A powerful effect 
can be obtained through inhibitors of hepatic cholesterol 
biosynthesis, as reported for example, with compactin 
(Ejiiia, 1985) and other competitive inhibitors of HMG-CoA 
reductase. 
In contrast to LDL, as shown in Fig. 2, HDL prevents or 
reverses atherosclerosis by mediating reverse cholesterol 
transport. In this process cholesterol is removed from sites 
of deposition, such as arterial wall or tendon xanthomas and 
delivered to the liver for biliary excretion (Glomaet, 1968). 
Thus, reverse cholesterol transport renders HDL or some of 
its subfractions to be antiatherogenic. Because of the 
inverse association of HDL with the incidence of CHD, as 
demonstrated by a number of clinical and epidemiological 
studies (ULelil et a.i. 1988; BahJLfiJi et <xl, 1980; Tyroler, 
1980; Miller. 1980) major interest has now been focussed on 
this lipoprotein. HDL form a heterogenous group of particles 
which can be divided on the basis of density, into two 
subfractions HDLa and HDL3. The concentrations of these sub-
fractions vary independently and they have separate 
le 
metabolic pathvjays (b^ikklla. 1981). HDLz is larger, less 
dense and contains more phospholipid and cholesterol than 
HDLa. Their concentration is influenced by many physiologic 
variables such as hormones, diet, sex and physical 
activity. In contrast to other lipoproteins, HDL is not 
turned over as a single compound. Its constituents may enter 
and leave the mother particle at different rates and undergo 
exchange or bidirectional shuttling between HDL and other 
lipoproteins or cell membranes. HDL precursors relatively 
poor in cholesterol would appear to be excellent candidates 
for reverse cholesterol transport by virtue of their 
considerable capacity for uptake of cholesterol and LCAT 
induced 'cholesteryl ester core formation. As shown in Fig. 
2, HDL3 acts as an acceptor of cholesterol, phospholipids 
and apoproteins that are released during degradation of 
VLDL and chylomicron by lipoprotein lipase at extrahepatic 
capillary beds. Upon this process HDL3 is transformed into 
HDL2 fPatsch &L ctl. 1978). It has been speculated that 
HDL2 could lose only part of its surface lipid into the 
liver and be converted back to HDL3 which is returned to 
plasma and starts the circle again. The process of 
conversion of plasma HDL3 to HDL2, involving neutral lipid 
exchange and role of triglyceride lipases, has recently been 
documented by Deckel baum <?t a.1 (1986). 
The incidence of CHD has been correlated positively with 
IT 
high levels of LDL-cholesterol and negatively with high 
levels of HD^-cholesterol (LI ^i a.1, 1988). However 
controversy exists regarding the relative importance of HDL 
subtractions. The relatioship of HDL subfractions to alcohol 
consumption, other life style factors and CHD was recently 
evaluated in a study made by Djehl el al (1988). These 
findings suggested that HDL-cholesterol as well as 
HDLz-cholesterol may be related to coronary risk and 
indicated that the protective effects of alcohol 
consumption may be mediated via this subfraction. In another 
study, distribution of HDL subfractions was determined in 
two groups of subjects with different coronary risk indices 
fflri ffIn &t al , 1988) and it was suggested that the level of 
these subfractions might provide a better index of coronary 
risk than that of total HDL-cholesterol, as conventionally 
employed in many epidemiological studies. It has also been 
documented that HDL2 subfraction has a stronger negative 
relationship with atherosclerosis risk than total HDL or 
HDL3 (Elaenberg, 1984). 
Plasma lipoprotein abnormalities are also common in patients 
with diabetes mellitus (tLLkkJJLa, 1984). They are of 
considerable clinical interest because of their relationship 
to atherosclerosis. The excess of CHD and other 
atherosclerotic vascular diseases associated with diabetes 
has often been attributed to the disordered lipoprotein 
t8 
metaboltara (Ganda, 1980). Diabetes is moat commonly 
associated with hypertriglyceridemia and elevation in VLDL 
levels (BfiiiE, and KxafiJOfir., 1988). Macrophages from insulin 
deficient mice have also shown increased activity of HMG-CoA 
reductase and subsequently an increased rate of cellular 
cholesterol synthesis (Kraemer. 1986) and subnormal HDL 
cholesterol levels are reported in untreated diabetic 
patients fNlkkila. 1981). A profound decrease in the 
activity of lipoprotein lipase is also observed in diabetes 
mellitus and a decreased secretion of lipoprotein lipase by 
murine macrophages has been reported (ELeiuc and Kxaemer.. 
1988). 
B. PLATELET AGGREGATION A N D ATHEROGENESIS 
It is well known that the excessive deposition of components 
of the blood including fibrin and platelets, onto the 
vascullar intima is responsible for the development of 
atherosclerotic plaques. The association of platelets with 
the atherosclerotic lesions has been repeatedly documented 
fFnggJQttQ et at 1984; Faggiotto and Eaa^,1984). The lesions 
may develop as a result of blood vessel injury, platelet 
adhesion to the injured site, the release of platelet 
derived growth factors, and the ensuing migration and 
proliferation of smooth muscle cells fMugtard et ctl , 1988). 
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Numerous constituen-bs released by platelets such as 
vasoactive amines, lysosomal enzymes, thromboxanes, 
prostaglandins and nucleotides and nucleosides may be 
injurious to endothelium. Diet induced changes in plasma 
lipids and intrinsic platelet alterations have been 
investigated in several studies (Joist et at, 1976; Zucker 
et cLl, 1988) . 
In CHD patients increased sensitivity of platelets to 
aggregating agents (Yamazaki et a.1, 1976; Gor.maeni et al , 
1977) or a tendency to disaggregate more slowly following 
ADP-induced aggregation (Pavis «t ctl. 1978) have been 
reported. Platelet activation is thought to be important in 
the generation of atherosclerotic disease (Weksler and 
Nachman. 1981). Takapl et al (1988) demonstrated that 
thrombin activated platelets or substances shed by activated 
platelets increase both the rate of esterification of 
cholesterol and accumulation of cholesteryl ester in 
macrophages. These observations suggested that platelets may 
contribute to lesion progression by enhancing foam cell 
formation. The atherogenic properties of lipoproteins are 
not restricted to their role in cholesterol and lipid 
metabolism but also involve their effect on blood platelet 
activity (Aviram, 1988). The possible effect of plasma 
lipoprotein concentration on the function of circulating 
platelets becomes of importance in the light of accumulating 
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evidence that hyperlipidemia, platelet function, and 
thrombosis are interrelated and directly influence the 
atherosclerotic process. 
Considerable evidence suggest that hypercholesterolemia, 
particularly the increase in LDL-cholesterol fraction, is 
associated with increased platelet aggregation (Carvalho et 
al, 1974). Patients with atherosclerotic disease are also 
reported to have enhanced platelet activity (Knapp et al, 
1986). Platelets from patients with FH have been found to be 
hypersensitive to aggregation fCarvalho et al. 1974), to 
contain increased amounts of cholesterol and phospholipid 
(Shaatrl «t al, 1980; Nordav and Eiid^ LSi, 1971) and to 
produce increased amounts of thromboxane Aj (Tremoli ed al. 
1979). The high levels of circulating LDL, responsible for 
hypercholesterolemia in these patients, could result in 
increased platelet activation irt vivo, which may in turn 
potentiate arterial injury and allow for cholesterol 
accumulation in the arterial wall. Incubation of platelets 
in vitro with cholesterol rich liposomes has also been shown 
to increase platelet aggregation and platelet thromboxane 
production (Stuart &t al, 1980; Worner and Patscheke, 1980). 
It has also been found that platelets possess specific 
binding sites for LDL (Avlram e-t a.1 , 1981) and these sites 
are qualitatively different in FH derived platelets, that 
are hyperreactive when aggregation and release responses are 
•toated in •vitro. In animals a similar en}iancemont in 
platelet function could be induced by a cholesterol rich 
diet (Over.qohl et al. 1975; ikiijaii ^t a.1, 1976). Enhancement 
of thrombin-induced platelet aggregation by LDL from 
diabetic patients was reported recently by Watanabe et a.1 
(1988) and this may contribute to the accelerated 
development of atherosclerosis in diabetes mellitus. 
Excess LDL may by itself damage endothelium (Heurjksen «?t 
ctl, 1979a) but, in the presence of sufficient HDL no damage 
ensues (Heuriksen et a.1, 1979b). One method to reduce early 
lesion formation in the atherosclerotic process is to either 
lower LDL or raise HDL levels, and a second less explored 
possibility might involve use of redox drugs designed to 
inhibit oxidative processes. Platelet activation may be 
inhibited by drugs interfering with various biochemical 
events. These include inhibitors of arachidonic acid 
metabolism, thromboxane A^ antagonists, adenylate cyclase 
activators, phospholipase C inhibitors and calcium channel 
blockers fWitiak et al, 1988). Clofibrate (Yamamoto Gt a.1, 
1980) inhibits the activity of phospholipase Aj possibly 
through an indirect mechanism. Aspirin inhibits cyclooxygen-
ase and substituted imidazole inhibits thromboxane A2 
synthesis fMoncada et al, 1985). Several other antilipidemic 
compounds have been found to be antiaggregatory and tlieir 
mechanisms of action have recently been discussed (WJJiiiik 
^ ^ 
at at. 1988). In view of these findings, the possibility-
exists that inhibition of platelet function might retard 
atherogenesis when such agents are given over very long 
periods of time. 
C. MECHANISM OF ACTION OF O T H E R HYPOLIPIDEMIC C O M P O U N D S 
Although our studies are specifically concerned with the 
mechanism of hypolipidemic action of HMG - an inhibitor of 
cholesterol biosynthesis, we shall briefly discuss tlie 
action of other agents, widely used as lipid lowering drugs. 
This might help to understand the mode of action of HMG. 
Probucol has been reported to effectively reduce plasma 
cholesterol in human and a number of animal species 
(Mlettlnen and Toivonen. 1975; HariZi, 1979; aiioaQn <?t ai. 
1981). It also affects the composition and in vitro 
catabolism of LDL in types Ila hypercholesterolemia (Daudet 
et al,1986). It increases the activity of plasma lipopi'otein 
lipase and decreases HDL- and LDL-cholesterol concentration 
in rats (Strandberp et al, 1981). Probucol prevents the 
development of macrophages into foam cellsf by inhibiting 
the lipid storage in macrophages (Yamamoto GL CLL , 1986a). 
These results coincided with the clinical findings that 
probucol causes a more marked regression of xanthomas 
than would be expected from the extent of lowering of 
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LDL-cholesterol. ProbuGol seems to act by increasing LDL 
removal from plasma by an LDL receptor independent mechanism 
(Keaaniemi and GxundiLf 1984),as it causes moderate reduction 
in LDL-cholesterol in non familial hypercholesterolemics 
(Simaon et al, 1984) and a smaller decrease in FH patients 
(Durrington and tliil^ r 1985; Efiiiin ^t ctl, 1986). A marked 
decline in HDL-cholesterol has been a constant finding 
(Kesaniemi and GxundiL, 1984; Eailln et ctL. 1986) and circula-
ting HDL in probucol treated patients are smaller than in 
controls (Yamamoto et al, 1986b). Analysis of LDL 
composition demonstrated that LDL cholesterol lowering 
effect of probucol in FH was entirely due to reduction in 
the proportion of cholesterol in LDL with no reduction in 
LDL mass, whereas in non FH a reduction of both LDL mass and 
apoB was achieved. A decrease in HDL2 fraction was also 
observed by probucol which is not mediated by lipoprotein 
lipase or hepatic lipase (tLelxfi. and TlkKanen, 1988). 
Fibrates are orally active compounds with a relatively long 
plasma half life. Among fibrates, clofibrate (CPIB), which 
combined maximal effectiveness and minimal toxicity in the 
initial screen, was widely used in the management of 
hyperlipoproteinemia in man. More recently, however, due to 
questionable activity in the secondary prevention of athero-
sclerosis (Coronary Drua. Pro.iect. 1975) and to the 
observation of untoward effects in primary prevention 
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(Gommitttoa a£ HidLiicJuLaJL Invjaatigatox^, 1978), Lho uoo of 
CPIB has become increasingly circumscribed. Among side 
effects, proliferation of peroxisomes in rodents has been a 
key target for chemical and pharmacological studies.A number 
of clinical trials have constantly shown that CPIB reduces 
plasma triglyceride levels substantially, affecting both 
VLDL and LDL associated triglycerides. This reduction is 
more evident in hypertriglyceridemic patients but less 
marked in normotriglyceridemic subjects (Hunninghake GI cil., 
1981; Crfliia£. and Gxuadz, 1981). 
The cholesterol lowering activity of CPIB is less dramatic 
and seems to depend on individual basal levels. In large 
series of hypercholesterolemic patients, a 10-15% reduction 
of total cholesterol and LDL-cholesterol has been reported 
(Grouae and Grundy, 1981; Hunninehake et ai. 1981), Besides 
inhibiting cholesterol biosynthesis at the step involving 
conversion of acetate to mevalonate, CPIB also affects 
several other metabolic pathways. Inhibition of fatty acid 
synthesis (t^arappudakis, 1969) and stimulation of adipose 
tissue lipoprotein lipase CTolman et ctl, 1970), adenyl 
cyclase (Green et ciL, 1970) and hepatic acyl-CoA hydrolase 
(Rorrebank,1979) has been reported. Inci'ease in LPL activity 
results into increased catabolism of VLDL and elevated 
HDL-cholesterol levels, thus it helps in mobilisation of 
tissue cholesterol. Hazzard et a.1 (1984) demonstrated 
ffCJ 
significant. decrease in plasma cholesterol and 
triglycerides, VLDL-cholesterol and triglycerides and an 
increase in HDL-cholesterol upon clofibrate feeding. 
However, it was associated with increase in reports of 
nausea. The mechanism by which CPIB exerts its effects on 
plasma lipoproteins is most likely related to an increased 
catabolism of triglyceride rich lipoproteins with the 
increase in LPL in adipose tissue and postheparin plasma 
without affecting a hepatic lipase (Goldberg et al, 1979). 
CPIB exerts, most likely, a primary effect on the production 
of LPL by tissues. On the other hand, the increased LPL 
activity may also result from the elevation of the apoC-II 
content of VLDL, the physiological activator of the enzyme 
(Bengstsson and Ollvecrcna, 1980), after treatment with CPIB 
and other, fibrates in hypertriglyceridemic patients 
fNaruszewiez et al , 1980; SLcanceschini et cil. 1985). 
Halofenate, structurally related to clofibrate is hypolipid-
emic and hypouricemic (Sirtori et al. 1972) and effective in 
lowering serum triglycerides in rat (Kritchevsky and Xfipjpcr., 
1972), Bezafibrate, a fibric acid derivative, has boon 
reported to lower plasma triglycerides in hypertriglyceride-
mic patients (ELLafinbexg. ^^ <^ t» 1984) and was effective in 
reversing most, if not all, of the abnormalities in 
lipoprotein composition,structure and functionality detected 
in these patients. It decreased plasma total- and VLDL-tri-
^G 
glycerides by about 40%-60% fSchwandt et a.1, 1982; Vessbv et 
Oil, 1980). In hypertriglyceridemic patients bezafibrate 
treatment often resulted in a rise of circulating LDL 
levels (Qlgson, &t al, 1977). These different responses seem 
to reflect in part the effect of bezafibrate on LPL-induced 
VLDL-LDL conversion (Vessbv et a.1, 1982) and on LDL 
catabolism (aj:raHLari. «?t a.1. 1982). LDL particles modified by 
bezafibrate bind to LDL receptor and down regulate the LDL 
receptor activity better than the pretreatment lipoproteins 
(Klienman et ai, i985). 
Fenofibrate, another analogue, is more potent than the 
previously described compounds, being fully active at a 
daily dose of 300 mg (Ressner and Qxii, 1981). It is markedly 
effective in patients with type II and IV hyperlipidemias 
(Franceschini et al, 1985) as well as in subjects with 
familial combined hyperlipidemia (WeigwQller et al, 1984) in 
decreasing total plasma cholesterol and triglyceride levels. 
However, HDL-cholesterol levels were unchanged in type II 
and in combined hyperlipidemia (t^almendier and QgLcrolx. 
1985). The mechanism of hypolipidemic effect of fenofibrate 
is different from that of parent compound involving 
its effect on lipoproteins as seen in subjects with FH as 
well as combined hyperlipidemia. An increase of apoC-II 
content in VLDL (Franceschini et a.1, 1985) was consistent 
with the observed increase in LPL activity after fenofibrate 
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treatment (Heller and Harvangt. 1983), which may result in 
increased HDL-cholesterol levels particularly in 
hypertriglyceridemic condition. In a recent study (Olivier 
et a.1, 1988) using mice as the model for drug screening, 
decrease in plasma triglycerides and VLDL-triglycerides was 
associated with an increase in HDL-cholesterol in animals 
receiving standard diet. On the other hand in hypercholes-
teroleraic mice, fenofibrate lowered total plasma cholesterol 
at the same time increasing HDL-cholesterol, 
Ciprofibrate is, apparently, the most potent available 
fibrate, being fully active at 100 mg/day (Qlsspn and Qro., 
1982). It is effective in all kinds of hyperlipidemias 
(Illlngworth et al, 1982). Detailed studies on the mechanism 
of action of ciprofibrate have not been carried out but 
reports indicate that it differs essentially in dynamic and 
kinetic properties (Slrtori and Franceschlni, 1988). 
Gemfibrozil, another fibrate, also affects triglyceride ricli 
lipoproteins. It has been found to be effective in both men 
(Shepherd et a.1, 1985) and mice (Olivier et a.1, 1988). A.s 
with other f ibrates, a rise of LDL-cholesterol has been 
detected with a decrease of apoB/cholesterol ratio. As 
plasma apoB levels were unchanged during treatment, a 
cholesterol enrichment of LDL, rather than an increase in 
the number of LDL particles has been suggested (Vega and 
Srundii, 1985), The influence of etofibrate on LDL metabolism 
2Q 
was recently reported in a group of hypercholesterolemic 
individuals (ggries et al, 1988) with a reduction of plasma 
cholesterol as well as cholesterol in VLDL and LDL 
fractions. Cholesterol content of HDL did not, however, 
change although its total mass rose by 29%. But the 
catabolism of LDL was reported to be increased without 
affecting its synthesis. Emijp &t al (1988) demonstrated the 
action of etofibrate involving the enhancement of 
esterification of fatty acids and gycerol in adipose tissue 
and increased utilization of triglyceride precursors in 
other pathways causing a decreased production of 
triglycerides. The reported findings are indicative of 
multiple mechanisms responsible for lipid regulating effects 
of CPIB and its analogues. 
The development of specific inhibitors of HMG-CoA reductase 
has considerably widened the therapeutic opportunities in 
hypercholesterolemic patients. Compactin and lovastatin 
(mevinolin) are potent competitive inhibitors of HMG-CoA 
reductase. A part of their structure closely resembles the 
HMG moiety of HMG-CoA and the enzyme, HMG-CoA reduGta.'jo. 
binds both the compounds with high affinity (Paolettl and 
EoJJL. 1987). These drugs have been used to reduce plasma 
cholesterol levels in many animal species (Alberts ^^ ctl, 
1980; Kovanen et al. 1981; Tobert e£ al, 1982). In clinical 
studies mevinolin and compactin effectively reduced plasma 
2Q 
LDL iii normal ClcbarJi. ot al,1902) an woll aa in aubJocLn 
with heterozygous FH (Bilheimer <et aL. 1983) and a 
compensatory increase in the receptor mediated catabolism 
of LDL was found (Grundy and Bilheimer, 1984). In patients 
with type Ila and lib hypercholesterolemia a mean 
reduction of 32% in serum cholesterol was reported after 
lovastatin treatment (The Lovastatin Study Group II, 1986). 
Goldstein and Brown (1984b) proposed that statins (compactin 
lovastatin and simvastatin) lower plasma LDL-cholesterol by 
inhibiting cholesterol biosynthesis and by increasing the 
number of LDL receptors. Addition of bile acid sequestrants 
further activates receptor mediated catabolism of LDL 
(iLfiAJl and Grundy 1987). An increase in HDL levels has been 
reported in several studies (HasLg. et cci. 1986; tkiL <st <=i-^ > 
1988) or the levels have remained unchanged (Mabuchi «?t a.1, 
1981; Illlngworth and SaxjLon, 1984). 
The mechanism of action of lovastatin differs from that of 
probucol (EfiJLstfi. and Tikkanen, 1988). Lovastatin therapy 
resulted in the increase of both HDL- and HDLz-cholesterol 
whereas with probucol HDL-cholesterol was markedly decreased 
mainly because of reduction in HDL2. Triglycerides remained 
unaltered during probucol treatment. Also, no significant 
changes in lipase activities were observed during lovastatin 
therapy indicating that these enzymes were not involved in 
its action. A new specific inhibitor of cholesterol bio-
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nynthonin, monacolin M, abructurcilly rolnt-od Lo tnovinoiin W«M 
isolated from cultures of a strain of Monascus ruber but the 
inhibition of HMG-CoA reductase was slightly less than that 
of mevinolin (Endo. «t aL, 1986). Recently, simvastatin 
(MK-733) was found to be a potent inhibitor of cholesterol 
synthesis in-heterozygous FH (tloJLet a.L. 1988). It inhibited 
the absorption of cholesterol from the gastrointestinal wall 
in cholesterol fed rabbits (Fumiaki et at. 1988). Triparanol 
fBhattacharvA and EitafiH, 1984), tibric acid (Persira and 
Holland, 1974) and tiadenol (Baggio et ctL.1979) are also 
cholesterol lowering agents. Tiadenol is remarkably 
effective in inhibiting fructose induced hypertriglyceri-
demia but its mode of action differs from that of clofibrate 
and related compounds (Franceschini et cil, 1981). 
Nicotinic acid is possibly the oldest lipid lowering drug. 
Large doses of this drug rapidly reduced plasma 
triglycerides by lowering VLDL in normal and sucrose diet 
fed mice (01 ivier et a.1. 1988). The reduction in 
triglycerides was reported to be due to decreased production 
of VLDL (Grundii et ai, 1981). 
To overcome the difficulty of obtaining adequate compliance 
with nicotinic acid treatment, because of the drug's 
numerous side effects, several analogues and derivatives have 
been tested but no clear advantages have been gained over 
the parent drug (Grapaldi et at,1988). Acipiraox, a nicotinic 
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acid analogue, was found t-o inhibit, adipose tissue lipolysis 
thereby reducing the FFA flux to the liver, resulting into 
less production of VLDL (Stirling et al, 1985). In recent 
study, LDL-cholesterol decreased in type II whereas a rise 
was observed in type IV patients after acipirnox treatment 
(Crepaldi et al, 1988). Acipimox did not increase LPL 
activity in men unlike clofibrate (Stuvt et CLI , 1985). 
However, adverse events like skin reactions, gastric 
disturbances,heart burn, epigastric pain Gtc. were reported 
during the treatment (Crepaldi et al, 1988). 
An alternate approach towards the control of cholesterol 
level is the use of bile sequestrant resins. The mode of 
action of bile acid binding resins is apparently fairly 
simple: bile acids, which are bound to these resins in the 
intestinal lumen, are not reabsorbed and are excreted with 
feces. These sequestring agents, thus, interfere with the 
entero-hepatic circulation of bile acids. Since bile acids 
are synthesized in the liver from cholesterol, as a result, 
cholesterol catabolism is enhanced. After prolonged treatme-
nt hypochloaterolemia is observed. However, there are some 
events that do not fit in this simple scheme. Homozygous 
type II patients are insensitive to cholestyramine inspito 
of increased level of fecal bile acids rMoutafis et al. 
1971). The LDL receptor pathway plays a role in the action 
of bile acid binding resins (.Shepherd et al. 1980). 
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D. ACTION OF 3-HYDROXY-3-METHYLGLUTARIC ACID CHMG) 
The implication of blood lipids as a contributing factor in 
the pathogenesis of atherosclerosis has led to widespread 
search for compounds which safely and effectively lower the 
concentration of lipids in blood and, hopefully, in tissues. 
Since more than 70% of the total input body cholesterol is 
derived from de riox>o synthesis in human (Dietschy and 
Wjlaon, 1970), it is expected that compounds inhibiting 
cholesterol biosynthesis may prove useful in combatting 
hypercholesterolemia. The most suitable target for this 
inhibition would be HMG-CoA reductase, the rate limiting 
enzyme of cholesterol biosynthesis fRodwell et al. 1976). 
HMG is known to inhibit cholesterogenesis between HMG-CoA 
and mevalonate (RablnoHJta and Qiinin, 1954) and 
competitively inhibits the enzyme HMG-CoA reductase 
(Flrnoffnari and Rodwcil, 1965). 
HMG-CoA hydrolase is known to catalyze iln. x>ix}o formation of 
HMG in a number of species (Dekker et a.1, 1958). The 
hypolipidemic activity of HMG has been studied in ratn 
fYou3uf7.a1 and Siddiai. 1976a,1977a; Frannesconi et ai,1987) 
rabbits (luiuiiLi. and Slddlai. 1974; LupifiH ^^ ^^ - 1973), 
hamsters (Fadova et. al • 1982) and humans (Yousuf zai et al 
1976b; Lupjen et ctl. 1973). A support to the hypolipidemic 
action of HMG is also obtained from the observation that low 
33 
incidence of CHD in Hctssai tribesman is related to their 
high consumption of cow's railk (Richardson, 1978), known to 
contain HMG (tlann, 1977). 
It is now considered a potential hypolipidemic compound 
often named as 'Mevalon' (^ LncA «t al, 1986) or 'Meglutol' 
(Correeelongue. 1985). Most of the work on the hypolipidemic 
action of HMG showed that it had no hepatotoxic effect at 
the microscopic level (.BSLB. ^^ ct^ » 1968). Lack of clinical 
and laboratory signs of pathological effects at hepatorenal 
level was reported f Bonavita et al, 1984) and no change in 
the liver function occured (£^rsia. ^f- al-. 1986). 
HMG effectively counteracted Triton WR-1339 induced 
hyperlipidemia in rats (Yousufzai and Slddiqi, 1976c) and 
hyperlipidemic effects of heated corn oil and cholesterol 
(Yousufaal and Siddlqi, 1977a). Since consumption of 
saturated fat is known to contribute to the development of 
CHD, it was of more practical value to find the effect of 
HMG on tissue lipids of animals kept on high levels of 
different dietary fats. HMG also prevented the rise of serum 
and liver lipids of rats fed with high percentage of lard, 
butter and hydrogenated vegetable oil (Yousufzai and 
RiddJQi. 1977a). The marked lipid lowering effect of HMG in 
serum and liver of butter-fed rats is interesting in view of 
the fact that affluent persons, more prone to CHD, consume 
larger amount of butter. As decrease in lipid parameters in 
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one tissue was not accompanied by an increase in other 
tissue, the effect of HMG on catabolism of lipids is more 
likely. HMG offered total protection against the lipemic 
effect of ethanol both in men and ratp (Youauf zai and 
Siddiai. 1976b), possibly by inhXbiting the mobilization of 
FFA from endogenous lipid stores and it was also effective 
against the lipemic and atherosclerotic response of massive 
doses of Vitamin Dz (Yousufzal and Slddigi. 1976a). High 
carbohydrate diets are known to produce hypertriglyceridemia 
and enhanced synthesis of VLDL as well as secretion of 
VLDL-triglycerides ( S M J L £ &t at. 1971) and different kinds 
of dietary carbohydrates are important in relation to 
hyperlipoproteinemia (Aniar <st al, 1970). Hence it was 
desirable to carry out studies on the effect of HMG in rats 
given high carbohydrate diet. With all types of dietary 
carbohydrates, HMG had a significant cholesterol and 
triglyceride lowering effect (Yousufzai and Siddlgi. 1977b). 
The action of HMG seems to be independent of the type of 
carbohydrate in the diet in preventing liypertriglyceridemia 
and hyperlipoproteinemia produced by dietary carbohydrates. 
Lijpien <S't a.L (1979) found usefulness of HMG in tlie treatment 
of FH patients without any evidence of adverse clinical or 
biological effects. All patients maintained excellent comp-
liance to medication. A unique experimental model for FH has' 
now been developed in the form of WHHL rabbits. Van Mi^ eluLLli. 
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^t al (1984) reported that IIMG appears to bo oqua]ly 
effective in this animal model similar to comt>actin which 
is also effective in heterozygous patients (Mabuchi &t a.1, 
1983) . 
In recent years much interest Has been developed in the use 
of hypocholesteroleraic drugs as a protective measure against 
cholesterol gall stone formation (cholelithiasis). Observa-
tions have been made in hamsters showing that the addition 
of HMG to a fat free lithogenic diet resulted in a marked 
reduction of cholesterol gall stone formation (Krltchevsky 
®t cxl, 1978). Antilithogenic effect of HMG was further 
supported when it was found to be effective in reducing both 
bile cholesterol supersaturation and hypercholesterolemia in 
hamsters (P^cjov^ et al, 1982). The potentiality of the use 
of HMG against hyperlipidemia gets further support from 
several recent clinical studies. It appears to be useful foz-
the treatment of most patients with diet resistant polygenic 
hypercholesterolemia and of some patients with heterozygous 
FH (AnQjai «•' al, 1986). HMG treatment of hyperlipidemic 
patients for 8 weeks resulted in a significant reduction of 
total plasma cholesterol but not always a significant 
reduction of HDL-cholesterol (Bonavita et al, 1984). 
Since most of the lipid lowering drugs currently in clinical 
use (nicotinic acid, clofibrate, etofibrate) induoo 
lithogenic bile secretion, effect of HMG was ascertained on 
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•the bile lipid composition. In a double blind, placebo 
controlled study, carried out in 16 norrtiolipidetnic patients 
with asymptomatic radiotransparent gall stones, HMG exerted 
no adverse effect on bile lipid composition differing from 
other drugs (Padova <^t- ai» 1984).. 
Since hypolipidemic therapy is generally instituted for 
longer period and since some types of hypolipoproteinomias 
by themselves carry an increased risk of cholesterol gall 
atone formation (Ahlberg et al. 1980), the knowledge of the 
possible lithogenic effect of each drug may influence the 
therapeutic choice of the physician. In this respect HMG 
seems to be protective and safe, since its administration 
does not alter bile cholesterol saturation index even in 
subjects with pre-existing high risk of a lithogenic bile 
secretion. 
E. SCOPE OF THE WORK 
For the first time work from this laboratory indicated that 
HMG has hypocholesterolemic activity in rats ( DGR and 
Siddjql. 1967; 1968) resulting in grant of a US patent 
No. 3,629,449 dated 21.12.71 for a Process of Combatting 
Hyper-eliolester-olenvLa. Since then work from different labo-
ratories has unequivocally established the hypolipidemic and 
anti-lithogenic action of HMG (Gastaner and EaiQU.. 1978; 
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Icjrnr aiicl Gidcjigi • 1987) reauiting in grant of several 
patents (I^ Lrax and Siddiai. 1988). Therefore HMG could be a 
potential hypolipidemic drug of the future. In the present 
work attempt has been made to understand the possible 
mechanism of lipid lowering action of HMG. It involves the 
study of effect of intraperitoneal administration of HMG on 
the concentration of plasma lipids, lipoproteins and the 
composition of different lipoprotein classes. Three 
different groups of rats namely normolipidemic, 
hyperlipidemic and diabetic groups were used as the 
experimental animal models.. To confirm whether the action of 
HMG involves its interference with the metabolism of plasma 
lipoproteins, activities of post-heparin plasma lipases as 
well as tissue lipases were measured in HMG treated and 
control rata. A part of the work also consists of the 
effect of HMG administration on the aggregation of blood 
platelets. 
QL 
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A. MATERIALS 
1 CHEMICALS : The chemicals used were obtained from various 
sources as shown below. All glass distilled water was used 
in experiments. 
CHEMICAL. 
Acetyl ac&ton& 
Ac ry L ami d.& 
Aga.rQs& 
At loxa.n 
i ,21 4-Am.ir\Q-roa.ph.tf\o-s-alfor\tc acid. 
Ammorxixim. oxalato 
AnufTusnixmi per-sulfcitG 
Bovine serum albximin 
ChxilestGrol 
Chalic acid 
Coonuassie br-illiant blue R-250 
Dextran sulfate CMr 50,000:> 
Digi tonirx 
Dipherxylcarbazide 
Diphertylcarbazone 
Eth.ylene diamine tetracetate 
Cdisodiiim s a l tJ> 
SOURCE 
Koch-Light Lab. Ltd., 
England 
Sigma Chem. CO. , USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Centron Res.Lab.,India 
B.D.H., India 
May & Baker Ltd., 
England 
Sigma Chem. Co., USA 
J.T. Baker Ltd., USA 
Loba Chemie, India 
Sigma Chem. Co., USA 
Sochibo, France 
B.D.H..England 
Wilson Lab., India 
Veb Jena pharm Labor-
Chemie, Apolda ^ 
B.D.H., India 
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He par t rx—S&phcLrose 
HeptcLrxG 
HycLrog&ncLt&d. v&g&Lc±>le oil 
3-Hyd.roxy-3-meth.yLgi-utcLric acid. 
KGto-d.iastix strips 
(J-rruercapLoethanol 
N, N, N' , N'-im&Lh.ylGnG bisacrylamidG 
Orthophjosph/oric acid. 
P&rch.loric acid 
Plat&l&t aggrGgatiorx scrGerxing 
t e s t Kit 
Pyronin-Y 
Silicic cucid 
Sodixum. barbital 
Sodixim. lauryl sulphate 
Sodixun me taper iodate 
Sudan blacK B 
NtN.N* ,N'-Tetramethyl ethylene 
diamine 
Triethanolamine 
Triolein 
Tris ChydroxyiTiethyl^ aminomethaixe 
S i g m a Chom. C o . , UIDA 
Pharmacia Fine Chem., 
Sweden 
Glaxo Lab., India 
Hind Lever Ltd., India 
Calbiochem, USA 
Miles India Ltd., India 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Glaxo Lab., India 
Glaxo Lab., India 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
SEARL, England 
Sigma Chem. Co., USA 
Loba Chemie, India 
E. Merck, Germany 
Koch-Lig)it Lab. Ltd., 
England 
Ferrak Lab., GDR 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
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2 ANIMALS : Male albino rats, weighing about 200-300 g, 
purchased from a local animal supplier, were conditioned to 
animal house environment prior to the experiment. 
3 DIET : The following diets were used. 
a. BASAL DIET : Hind Lever Rat Feed was obtained from 
Hindustan Lever Ltd., India. 
b. FAT-RICH CHOLESTEROL DIET : Basal diet was mixed with 
hydrogenated vegetable oil(5%), cholesterol(2%)and cholic 
acid(13S), LBQ£. and Slddigj. 1968). 
B. METHODS 
1 EXPERIMENTAL DESIGN : Animals were conditioned for two 
weeks on basal diet prior to the experiment. Diet and water 
were given ad libttxm.. The animals were divided into six 
groups,each group comprised of at least five animals 
unless mentioned otherwise. 
I. NORMOLiPiDEMic CONTROL <NLP-G) : Rats in thls group 
were fed basal diet and received daily ImL normal 
saline c:t.p.:>. 
II. NORMOLipiDEMiG TREATED <NLP-T) : Rats Were kept on 
the same diet as in GROUP I but received 25 mg HMG/kg 
body weight, L.p., daily in 1 mL normal saline. 
in. HYPERHPiDEMic CONTROL <HLP-c> : Rats Were made 
hyperlipidemic by feeding fat-rich cholesterol diet for 
4/ 
three weeks and then returned bo basal diet and LronLi^id 
with 1 inL normal saline as in OROUP I. 
IV. HYPERi^iPiDCMic TREATED <HLP-T>: Rats Were treated as 
in GROUP III but received HMG as in GROUP II. 
V. bXADETic GONTHOu <DiiT-G): Uats Were injected alloxan 
(50 rag/kg body weight) i.xj. through tail vein. After 
48 hrs the animals developed diabetes (ketone bodlon 
and glucose were checked in urine with keto-diastix 
reagent strips). These rats were kept on basal diet and 
received daily 1 mL normal saline Ci.p.:>. 
VI. DIABETIC TREATED <DBT-T> : Rats Were made diabetic 
as in GROUP v but treated with HMG as in GROUP II . 
At the end of 15 day treatment, the rats in all groups 
were subjected to an over night fast (12-15 hrs). These 
animals were anaesthetized with ether,blood drawn by cardiac 
puncture and processed as described below. 
Heart and liver were excised, quickly washed, weighed and 
dropped into ice cold 0.25 M sucrose solution. 
2 COLLECTION OF BLOOD : 
1 For the /rcLC Lionatiorx of lipoproteins, ten rats 
were taken in each group. The blood was collected using 
EDTA as anticoagulant to give a final concentration of 
1-1.5 rag/mL. Blood was mixed gently by inversion 5 or ,6 
times and immediately cooled to 2 - 4 C in an ice bath. 
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As soon as possible the samples were centrifuged at 4 C 
for 30 min, at 2500 rpm. Plasma of 2 rats (identical in 
weight) was pooled in clean tubes and stored at 4 C, if 
necessary, for not more than 12 hrs. 
2 For plcLiGlGt a^grGgcLttorx studies, nine volume of 
freshly drawn blood samples were added to siliconized 
tubes containing one volume of 3.8% sodium citrate as 
anticoagulant and kept at room temperature. It was used 
to prepare platelet rich plasma, CPRP^ and platelet poor 
plasma. CPPPD. 
3 To obtain post-heparin plasma., fasted animals were 
injected heparin (50 I.U.) t.x>. through the tail vein. 
After about 10-15 min, blood was collected from the 
anaesthetized rat by cardiac puncture into chilled 
heparinlzed tubes. Centrifuged at 3000 rpm for 15 min at 
4 G and post heparin plasma was transferred to clean 
tubes and stored frozen until the separation of lipases 
by heparin sepharose chromatography. 
3 ANALYTICAL PROCLDURES : 
1 FRACTIONATION OF PUASMA LiPorROTEiNs : Lipoproteins 
were fractionated from plasma by precipitation as descr-
ibed by aaiLtLOxik and Albers (1986). Isolation of HDL/ 
and its subfractions HDLz and HDLa and a combined 
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fraction of VLDL+LDL was done in a two step procedure. 
Following solutions were used (Warnick et al. (1982). 
I Dextran sulfate (Mr 50,000) 20g/L, pH 7.0 
II Dextran sulfate (Mr 50,000) 40g/L, pH 7.0 
III MgClz.eiIzO 1.0 M,' pH 7.0 
IV MgClz.SHzO 2.0 M, pH 7.0 
Reagent A was prepared by mixing equal volumes of I and 
III to give final reagent concentrations as MgClz, 0-5 M 
and dextran sulfate, 10g/L , stored at 4 C. 
Reagent B was prepared by mixing 1 volume of II with 3 
volume of IV to produce reagent concentrations as MgClz, 
1.5 M and dextran sulfate, 10g/L^stored at 4 C. 
To 1 volume of plasma was added 0.1 volume of reagent A. 
Samples were mixed immediately and thoroughly on a 
vortex mixer at a slow speed to avoid foaming (final 
reagent concentrations in the reaction mixture were 
0.91 mg/mL dextran sulfate and 0.045 M MgClz) . The 
samples were allowed to stand at room temperature for 10 
min and then centrifuged at 5000 rpm for 30 min at 
4 C. The clear supernatant was used for the analysis of 
total HDL as well as for the fractionation of HDLa and 
HDL^. The precipitate was dissolved in 1 volume of 155 mM 
NaCl containing 1% SDS and used for the analysis of 
VLDL+LDL. 
For HDL subfractions, 0.1 volume of reagent B was added 
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to 1 volume of the above supernatant and mixed immediat-
ely. The final concentrations were dextran sulfate 
0.9 mg/mL and MgClj 0.136 M. Samples were allowed to 
stand at room temperature for 15 rain and then 
centrifuged at 5000 rpm for 30 min at 4 C. Aliquots of 
clear supernatant were used for HDLa analysis. 
The measured values for total HDL and HDLg were multip-
lied by 1.1 and 1.21, respectively, to correct for the 
dilution of samples by reagents. HDLz lipids were then 
calculated as the difference between HDL lipids and HDLg 
lipids. A multiplication factor of 0.9 was used for VLDL 
+LDL measurements. 
For the isolation of VLDL, 0.075 volume of 10% SDS 
solution was added to 1 volume of plasma. After well 
mixing, samples were covered with parafilm to minimize 
evaporation and incubated in a water bath for 2 hrs at 
37 C. These were then centrifuged at 10,000 rpm for 
10 min at room temperature. The VLDL pellicle floats at 
the top of the tube. The subnatant was carefully removed 
with a hypodermic syringe and discarded. The pellicle 
residue was washed with 0.1% SDS and dissolved in 1 
volume of 1% SDS by warming at 35°C for 10-15 min 
and suitable aliquots were analyzed for VLDL proteins 
and lipids. The measured values were multiplied by 1.075 
to correct for the dilution. 
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2 TURDIDIMETRIC SCRKKNINO rOK It YPCRUIPIDCMIA : T h e a m O -
unt of VLDL+LDL was measured in plasma as described by 
Bachorik and Albers (1986). Plasma samples (o.2 mL) were 
added to tubes containing 3.2 mL distilled water and 
mixed well. To each of these tubes, 0.1 mL heparin 
solution (2.5 rag/mL) and 0.5 mL CaClz solution (0.5 M) 
were added, mixed on vortex mixer and allowed to stand 
at room temperature for 15 min. A blank was also 
prepared in the same manner except that distilled water 
was substituted for the heparin solution. Since no 
standard lipoprotein was available, the absorbance measu-
red against blank at 600 nm in Sp&ctrorLtc 2i spectropho-
tometer was converted to mg lipoprotein/dL plasma by-
using the following formula suggested by Voelker (1971). 
mg lipoprotein/100 mL plasma = Cabsorbance x 9005 + lOO 
3 DETERMINATION OF HDL : Plasma HDL was quantitated by 
the turbidimetric method of [{itoshi (1986). A 50 i^L plasma 
sample was treated with 2.0 mL of a reagent containing 
0.1% dextran sulfate and 0.05 M MgClz- The samples were 
mixed thoroughly and after 10 min the absorbance at 660nm 
was measured in SpGctrorxic 21 spectrophotometer against a 
reagent blank. It measures VLDL+LDL. These samples were 
then treated with 0.2 mL of another reagent containing 
dextran sulfate (1.6%) and MgClz (0.8M) and vortexed. Now 
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tho abaorbanoo at 660 tun roflocba tho concern traLion oC 
VLDL+LDL+HDL. The difference between the two absorbance 
values, that measures the amount of HDL in plasma, was 
converted to mg lipoprotein/dL plasma as described above. 
4 AOAROSE GEL ELECTROPHORESIS OF PUASMA LIPOPROTEINS : 
Prior to electrophoresis plasma samples, stored at 4 C 
overnight, were centrifuged to remove chylomicrons, if 
any. The electrophoretic method of Melsen et al (1974) 
with some modification was followed. Agarose (0.83%) 
was mixed with BSA (0.3%) in 0.05 M sodium barbital, 
pH 8.6. The solution was applied to form a gel (6x8 cm) 
in a horizontal chamber. Plasma samples were mixed with 
agarose in a ratio of 1 : 1 at 60 C. Samples (40 ML) 
were applied through preheated micropippette tips, dipped 
in warm water, in preformed application zones in the gel. 
BroiDophenol blue mixed with agarose was placed in the 
first well and used as the indicator of the electrophore 
-tic run. The electrophoresis was performed in 0.05 M 
sodium barbital (pH 8.6) at a constant voltage of 80 V. 
The gel was fixed in a solution of methanol-ethanol-
acetic acid-water (47.5 : 3 : 2 : 47.5,V/V) for 2 hrs. It 
was washed and dried in an oven at 60 G until it becomes 
a transparent film on the glass plate and then stained in 
a solution of 0.2% sudan black B and 1.0% zinc acetate in 
60% ethanol for 4 hrs. The plate was rinsed under running 
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water and Kently rubbed witVi cotton wool to cloan OXCOMS 
stain on the plate. 
The concentration of lipoprotein classes was obtained by 
scanning the gel in a Dual WaxjGlength ScannGr (Model 
CS-90, Sh.imcicl2u:> . 
5 SDS-POLYACRYL.AMIDC GEL Ct^eCTROPHORESIS OF PLASMA UIPO 
-PROTEINS : Electrophoresis was performed in a 3-15% 
polyacrylaraide gradient gel in the presence of SDS by 
the method of Fa.irbank Gt al (1971) with some 
modification. A gradient maker pump and slab gel system 
of Atto Co., Japan was used for casting 3%-15% gradient 
gel. Concentrated stock solutions were mixed in two 
separate containers in the order and proportions as 
described below to give final concentrations of 15% and 
3% acrylaraide. The solutions were poured with the help 
of gradient maker into a glass cassette, the plates of 
which were separated by 2.0 mm thick spacers. Bubbles 
and leaks were avoided and a comb providing a template 
for 12 sample wells was inserted into the cassette Just 
after pouring the solution. The polymerization was 
complete in about 2 hrs. The comb was I'emoved and the 
wells thus formed were washed and overlaid with 
distilled water. 
A, Stock aoliLtlaaa. Lor. El.e-G.tr.opJiore3ls -"All reagents were 
prepared in all glass distilled water. 
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i. Cone. a.cvylamidG-btscicrylam.i.cl<°' 
Acrylamide (40 g) 
Bisacrylamide (1.5 g) 
Dissolve in water and make upto 100 mL. 
1.0M Tris HCl, pH 8.0 (40 mL) 
2.0M Sodium acetate (10 mL) 
0.2M EDTA (10 mL) 
Adjust pll to 7.4 with glacial acetic acid and make 
upto 100 mL with water. 
3. SamplG Du/fGr contained 2% SDS, 20% sucrose, 2 mM EDTA, 
10 mM Tris HCl, pH 8.0, 3.75% ^-mercaptoethanol and 
0.002% pyronin Y. 
4. 20% SDS 
5. 1.5% APS 
G. 0.5% TEMED 
7. Electrophar&sis Buffer 
10 X Buffer (25 mL) 
20% SDS (2.5 mL) 
Make upto 250 mL with water. 
B. Gfil. composition (per i mL of. polymerizing solutiona 
isix. 3-15% gradient g^X : 
3X gel 15X gel 
Coru:. cu:rylanitdLe-bisacrylam.i<i& 0 . 3 mL 1 . 5 mL 
DistiLl&d xoa-ter 2 . 5 mL 1 . 3 mL 
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3X yol I'JX <|r-J 
iO X Buffer 0.4 mL 0.4 mL 
SDS 0.2 mL 0.2 mL 
TEWED 0.2 mL 0.2 mL 
/IPS 0.4 mL 0.4 mL 
Samples of lipoproteins for electrophoresis were prepared 
by the method of Connelly and Kukals. (1982) with 
modifications as described. An aliquot of lipoprotein 
sample (10 M L ) was mixed with isopropanol (40 /JL), 20% 
SDS (5 /JL) and Saittple Buffer (25 pL). Samples were then 
heated in a boiling water bath for 5 min. Samples 
containing ^ 15-20Mg protein were applied to the wells of 
preformed gradient gel. Electrophoresis was carried out 
at a constant current of 50 V in Electrophoresis Buffer 
until the tracking dye was 1 cm from the end of the slab 
gel. The gel was immediately subjected to fixing and 
staining witli coomassie brilliant blue (0.1%) in 25% 
isopropanol and 10% glacial acetic acid for 4 hrs. 
Destaining of the gel was done in a solution containing 
acetic acid (10%) and methanol (5%) until the background 
became clear. 
6 PLATELET AaaREOATioN METHOD : Immediately aftor tho 
collection,blood was centrifuged in the following manner: 
I. To prepare platelet rich, plasma. CPRPS>. blood was 
centrifuged at 1500 rpm for 10 min at 25*^  C. PRP was 
50 
carefully romoved and kept In capped plan Lie tuboa at 
room temperature for duration of test. 
II. To prepare platelet poor plctsma. CPPP>, blood was 
centrifuged at 5000 rpm for 10 min at 25^ C. PPP was 
carefully transferred to capped plastic tubes and 
kept at room temperature. 
Platelet counting was carried out using an Impro-of^d. 
NeubcLU&r courxting chamtier. Aqueous solution of ammonium 
oxalate (1%) was used to dilute plasma samples (1:20) 
before counting. The platelet count of PRP samples was 
adjusted to ^ 300,000 platelets//jL by making appropriate 
dilutions with autologous PPP, Aggregation of platelets 
was measured in PRP samples in an ELvi 840 A^gregonustGr-
(Elvi Logos, Milano, Italy) using PPP as blank. Cuvettes 
containing plasma samples (225 ML) were placed in the 
thermostatized block of instrument (37 C). PRP samples 
were agitated during the observation by means of ferro-
magnetic agitation bars; speed of stirring was set to 
1000 rpm. To PRP samples, 25 /uL aggregating reagent(ADP, 
2x10 M) was added (final concentration of ADP was 
20 MM) and the aggregation response was recorded fox- few 
minutes by the recorder of the instrument. This shows the 
change in optical density after the addition of stimulus. 
The extent of aggregation is expressed as percent change 
in optical density, the difference between optical 
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donaity of I'PP unci that of r«P representing Y\d\d%. 
For in vitro studies, varying amounts of HMG (1.0-5.0 
rag/raL) were added to PRP derived from a control rat and 
platelet aggregation response was observed in a similar 
manner. 
7 DETERMINATION OF HEPATIC AND LIPOPROTEIN L I P A S E ACTIVITIES 
FROM posT-HKPARiN PLASMA : Affinity chromatography 
on heparin-sepharose columns was used to fractionate 
post-heparin plasma lipases according to the method of 
Boberp et aL (1977) with modifications as described. 
Plasma was diluted immediately with an equal volume of 
0.005 M sodium barbital - 0.45 M NaCl buffer (pH 7.0) to 
obtain a final NaCl concentration of approximately 0.3 M 
(for raaxiraura absorption of lipases from plasma to the 
heparin-sepliarose gel). A measured volume of tlie diluted 
plasma sample was then applied to hepaz'in-sepharose 
column (20x10 mm). The column had previously been equili-
brated with a 0.005 M sodium barbital-0.15 M NaCl buffer 
pH 7.4. A stepwise elution was carried out using barbital 
buffer with NaCl as indicated. The column was washed 
with approximately 10 mL of 0,005 M sodium barbital 
containing 0.3 M NaCl. Hepatic triglyceride lipase was 
eluted with buffer containing 0.72 M NaCl (6 mL) followed 
by elution of lipoprotein lipase with buffer containing? 
1.5 M NaCl (6 mL). 
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ASSAY OF LIPASE ACTIVITY : An etnulaion of triolein was 
used as the substrate. This was prepared by sonication of 
triolein in either high salt buffer (for hepatic triglyc-
eride lipase) or low salt buffer (for lipoprotein lipase) 
using a USE Sontprep 150 sonicator. The high salt 
buffer contained 0.2 M Tris, 0.75 M NaCl, 0.4% gum arable 
and 0.5% BSA, pH 8.8. The low salt buffer was of the same 
coroposition except that it contained 0.13 M NaCl and 
adjusted to pH 8.2. The final concentration of triolein 
was 2.26 raM in both the buffers. The substrate for 
lipoprotein lipase also contained pre-heparin plasma 
(60 /^L/mL) as the source of activator apolipoprotein. The 
enzyme assay was performed in a total volume of 0.1 mL. 
Reaction was started by adding 10 ML of the enzyme 
fraction to stoppered centrifuge tubes containing 90 ML 
of the preincubated substrate and tubes were then further 
incubated on a shaking water bath maintained at 28 C for 
30 min. The reaction was stopped by the addition of 6.0 
mL of solvent containing chloroform-heptane-methanol 
(200:150:7 V/V) to the assay mixture. An enzyme control 
was also run in the same manner. Free fatty acids were 
extracted and estimated by the method of Erim and Menahan 
(1981) as follows. 
About 330 mg of silicic acid was added to each reaction 
mixture and tubes were shaken 30 times by hand and 
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allowed to stand for 15 tnin at room temperature. The 
tubes were again shaken six times and centrifuged at 4000 
rpm for 5 min. The supernatant, containing the extracted 
free fatty acids, was decanted into another tube 
containing 2.0 mL of freshly prepared Cu-TEA solution 
(0.05 M Cu(N03)2, 0.1 M triethanolamine, pH 8.1,saturated 
with NaCl approx. 33 g/100 mL) . The tubes were sliaken 
vigorously on a mechanical shaker for 20 min and 
centrifuged for 5 rain at 4,000 rpm. Four mL of the upper 
organic layer was then treated with 2.0 mL of the colour 
reagent (0.5% solution of a mixture of diphenylcarbazone 
and diphenylcarbazide (5:95) in methanol). The resulting 
colour was read after 10 min at 550 nm in Sp&ctronic 20 
spectrophotometer against the enzyme control tube. The 
amount of free fatty acids was calculated from the 
calibration curve, prepared by using standard solution of 
palmitic acid in chloroform (5 ^M/raL). The enzyme 
activity has been expressed as /-vmoles FFA/mL/hr. 
8 DETERMINATION OF L I P A S E ACTIVITY IN LIVER IIOMOOENATE: 
To obtain 10% (w/v) horaogenate, the liver was homogenized 
in all glass (teflon coated pestle) Pot t&r-El-uejh^m. homo-
genizer containing 0.25 M sucrose and 10 mM Tris-HCl, pll 
7.4. Protein was estimated in the horaogenates by the 
method of Lowrv GL a.1 (1951). For the assay of lipase 
activity, aliquots of liver homogenate (10 t-iL) were added 
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to stoppered tubes containinR 90/JL preincubn tod subn trn t.o 
(2.26 mM triolein emulisified in high, salt buffer) and 
incubated on a shaking water bath at 37 C for 25 min. The 
reaction w<as stopped and free fatty acids were extracted 
and estimated in the same way as described earlier for 
plasma lipases. The activity of tissue hepatic lipase was 
expressed as /Jmoles FFA/mg/hr. 
9 DETERMINATION OF MYOCARDIAL L I P A S E ACTIVITY T h e 
heart was homogenized in the similar manner as described 
above for liver. Protein was estimated in the homogenate 
by the method of Lowrv et CLI (1951). The aliquots of this 
homogenate served as the source of lipase. The substrate 
had the following composition '. 2 mg triolein, 5.0 mL BSA 
(20%) and 2.5 mL NaCl (0.1 M ) , as described by Valreswari' 
and Tulpule (1980). It was emulsified by sonication in a 
MSE SofxtprGp 150 sonicator. The lipolytic activity was 
determined by adding 0.025 mL of homogenate to glass 
stoppered tubes containing 0.075 mL of pz-eincubated 
substrate at 37 C. The tubes were incubated foz- 25 min 
on a shaking water bath maintained at 37 C. The reaction 
was stopped by adding 6.0 mL of the chloroform-heptane-
methanol (200:150:7, V/V) solvent. The enzyme activity 
was measured by estimating amount of FFA released, 
spectrophotometrically as described earlier by the method 
of ErOJl and Menahan (1981). The activity was expressed as 
fuP^ 
pmolea FFA/mR/hr. 
10 ESTIMATION OF PROTEIN : Protein estimation was done 
according to the method of l^ owry et al (1951). Suitable 
aliquots of lipoprotein samples were diluted to 1.0 mL. 
Freshly prepared alkaline copper reagent (5.0 mL) was 
added to each sample and the samples were mixed thorough-
ly. After 10 min,0.5 mL of 1 N Folin's phenol reagent was 
added and the tubes were vortexed instantly. After 30 
min, absorbance of the developed blue colour was measured 
at 660 nra in a Sp&cironic 20 spectrophotometer, against a 
suitable reagent blank. From the calibration curve 
prepared by using BSA as the protein standard, amount of 
protein was calculated. 
11 DETERMINATION OF TRIGLYCERIDES : Triglycerides were 
estimated in plasma and lipoprotein fractions according 
to the method described by Annino and Gie.qe (1976). 
Aliquots of 0.5 mL of the test samples were taken in 
glass test tubes. Two mL of heptane,3.5 mL of isopropanol 
and 1.0 mL of 0.08 N sulfuric acid were added to all 
tubes. At the same time 0.5 mL of water was taken as the 
control sample and was treated in a similar way as the 
test samples. 
The contents of each tube were mixed for 20 seconds on a 
vortex mixer and allowed to stand for 5 min at room 
temperature. The upper heptane layer was carefully trans-
56 
ferrod to clean tubes. An aliquot of this extraGt(0.5 rnfi) 
was treated with 4.0 mL of isopropanol and 2 drops of 
6,25 M potassium hydroxide and mixed well. The samples 
were heated at 70 C for 10 min followed by the addition 
of 0.4 mL of periodate reagent and 2.0 mL of acetyl-
acetone reagent. The tubes were again heated for 10 
rain at 70 C, cooled to room temperature and absoi-bance 
was read at 425 nm against the blank set at zero 
absorbance in a Sp&c tronic 20 spectrophotometer. 
For standardization stock standard of 1000 mg triolein/ 
100 mL of isopropanol was prepared. Calibration curve was 
drawn using working standards of 50, 100, 200, 300 and 
350 rag/100 mL concentrations. The standard samples were 
analyzed exactly like the test one, except that 3.0 mL 
of isopropanol and 0.5 mL of water were added in tlie 
extraction step instead of 3.5 mL of isopropanol. It was 
found that an optical density of 0,5 was equivalent to 
300 mg/100 mL triglyceride concentration. 
12 DETERMINATION OF TOTAL, LIPIDS : The serum and lipopr-
otein total lipids were determined by the method 
described by Annino and Giasfi. (1976). To 0.1 mL of the 
test sample, 2.0 mL of cone, sulfuric acid was added in 
glass test tube. At the same time 0.1 mL of standard 
solution (700 mg olive oil/100 mL of absolute ethanol) 
and 2.0 mL of cone, sulfuric acid were added to another 
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"tube. The contents of the tubes were mixed well and 
heated in a boiling water bath for 10 min and then cooled 
to room temperature. An aliquot of 0.1 mL was 
transferred to a clean tube. In another tube 0.1 mL of 
cone, sulfuric acid was taken as blank. To all tubes 
6.0 mL of phosphovanillin reagent (1.2 g of vanillin 
dissolved in 200 mL of water and made upto 1 litre witVi 
orthophosphoric acid) was added with thorough mixing and 
the tubes were incubated at 37 C for 15 min. The 
absorbance was read at 540 nm in a Spec ironic 20 
spectrophotometer using blank to set zero absorbance. 
The amount of total lipids was calculated as follows : 
_ . , , . . , ^ ,^t ^ absorbance of test sample ___ 
Total lipids Cmg/dL^ « —r r- 7. 1 n -r- x TOO 
•^  absorbance of standard 
13 DETERMINATION OF PHOSPHOLIPIDS Phospholipids were 
determined by the method of Dartlott (1959) as modii'iod 
by Marinettl (1962), The lipoprotein or serum sample (0.3 
mL) was delivered into centrifuge tubes containing 3.0 mL 
of water. Five mL of freshly prepared 10% trichloro-
acetic acid (w/v) solution was added to all tubes. The 
tubes were allowed to stand for 10 min and centrifuged at 
3,000 rpm for 15 min. The supernatant was decanted and 
tubes were inverted on filter paper until practically all 
the supernatant was removed. The precipitates were 
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digested with 1.0 mL of perchloric acid (70%) on an 
electric digestion unit for about 45 min. On cooling to 
room temperature, 7.0 mL of distilled water were added to 
all tubes followed by the addition of 1.5 mL of ammonium 
molybdate (2.5%, w/v) and 0.2 mL ANSA reagent (0.25%, 
w/v). The samples were mixed on cyclomixer and heated in 
boiling water bath for exactly 7 min, cooled and read 
after 20 rain at 660 nm in a Spec ironic £0 spectrophoto-
meter. A calibration curve was prepared using potassium 
dihydrogen orthophosphate as standard (2 mg phosphorus/ 
100mL). Suitable aliquots of 0.1 mL-1.0 mL were diluted 
to 8.0 mL with 1.0 mL of perchloric acid and 6.9 mL-6.0 
mL of distilled water and treated in the same manner as 
the test samples. Under the experimental conditions, an 
optical density of 0.5 was equivalent to 16/Jg of 
phosphorus. The phospholipid values were obtained after 
multiplying the phospholipid phosphorus by a factor of 
25. 
14 DETERMINATION OF CHOLESTEROL : Total, free and estert-
fied cholesterol were estimated in serum and lipoproteins 
as described by Annlno and Gi^a^ (1976). To glass centri-
fuge tubes, containing 4.8 mL of isopropanol, were added 
0.2 mL of the test sample or 0.2 mL of the standard (200 
mg chole3terol/100 mL isopropanol). The contents were 
mixed, allowed to stand for 5 min and centrifuged at 
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3,000 rpm for 10 min. 
For total cholesterol, 1.0 mL of the supernatant was 
taken in glass test tubes and treated with 2.0 mL of 
ferric chloride reagent (70 mg of ferric chloi'ide 
hexahydrate/100 mL of glacial acetic acid) mixed 
immediately followed by the addition of 2.0 mL of cone, 
sulfuric acid with thorough mixing. For reagent blank, 
1.0 mL of isopropanol was used instead of supernatant. 
After 5 min the absorbance was read at 550 nm in a 
SpectTOTxtc 20 spectrophotometer using blank to set zero 
absorbance. 
For the determination of free cholesterol and cholesterol 
ester, 2.0 mL of supernatant was treated with 4.0 mL of 
acetone and 2.0 raL of digitonin solution (1.0 g of 
digitonin dissolved in 60 mL of absolute ethanol, diluted 
to 100 mL with water and mixed well). The tubes were 
allowed to stand in an ice bath for 30 min and then 
centrifuged for 10 min at 4,000 rpm. The supernatant was 
decanted completely. The precipitate was again waslied 
with 5.0 mL of acetone and dissolved in 1.0 jnL of 
isopropanol. At the same time, 1.0 raL isopropanol was 
taken in a clean tube to serve as blank. To all the 
tubes, 2.0 mL of ferric chloride reagent and 2.0 mL of 
cone, sulfuric acid wore added and the contontrv woro 
mixed well. After 5 min, the absorbance was read at 550 
GO 
nm in a SpGC ironic 20 apectrophotome'ter using blank to 
set zero absorbance. 
The total, free and esterified cholesterol were 
calculated as follows : 
^ ^ , .. , X , ^  ^j. -^  absorbance of test sample _,^ ^ Total cholesterolCmg/dLD • -r: r 7 1 n -r x200 
^ absorbance of standard 
_ . , » , ^ ^^ , -» absorbance of test sample ^ _,_, Free cholesterol Cmg/'dL3 " —n r- y 1 T -r xlOO 
absorbance of standard 
Choi, ester Cmg/dL3 • Total Cholesterol-Free Cholesterol 
C. TREATMENT OF DATA 
Unless mentioned otherwise, the percent change has been 
calculated in the following manner : 
„ . . Val.of control groun-Val.of treated group .^„ Percent change • i, . 5 ^ w =• i- xlOO 
" val. of control group 
Statistical analysis of data was done employing two 
tailed Student's t-Test. 
liU, 
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Effect of HMG on Plasma Lipids : All lipid parameters 
significantly increased in the plasma of hyperlipidemic as 
well as alloxan-induced diabetic rats in comparison to 
normolipidemic rats as shown in Table 1. The concentrations 
of cholesterol, triglycerides and total lipids in plasma 
were significantly decreased in both normolipidemic and 
hyperlipidemic rabs after intraperitoneal administration of 
HMG (Fig. 4) . Even though the decrease in phospholipids was 
not as significant as in other lipid parameters, the 
magnitude of reductions in lipid parameters very well 
correlates with the earlier observations (Eag. and Slddiql, 
1968). 
When diabetic rats were treated with HMG, significant 
lowering (p <0.05) of all lipid parameters in plasma was 
observed. The effect was more marked foz' total cholesterol 
(31.8%) than for phospholipids (22.9%) and triglycerides 
(14.5%). These results indicate that HMG has a more 
pronounced hypocholesterolemic effect in diabetic than in 
normal rats {Table- i . Fig- A.). 
Effect of HMG on Plasma Lipoproteins : The amount of higli 
density lipoprotein (HDL) and very low density lipoprotein 
plus low density lipoprotein (VLDL + LDL) was measured 
turbidimetrically in plasma of control and HMG treated 
animals belonging to various experimental groups. As 
TablG i 
Effect of HMG on Plasma Lipids 
<Valuea aro moan mg/dl ± SC; n = 5> 
ea 
GROUPS * 
I 
II 
III 
IV 
V 
VI 
I 
III 
V 
I 
I 
ND = 
NLP-C 
NLP-T 
HLP-C 
HLP-T 
DBT-C 
DBT-T 
vs II 
vs IV 
V3 VI 
vs III 
vs V 
V a l u o Q I 
Ind i c at ed 
Not dAlormir 
TOTAL 
LIPIDS 
469 ± 18 
382 ± 14 
1114 ± 33 
891 ± 24 
ND 
762 ± 43 
P <:0.01 
C-18.63 
P <0.05 
C-20.OD 
-
— 
p <0.001 
(+137.5) 
-
r> pa r o n I hoa < 
od. 
CHOLE-
STEROL 
111 ± 5 
88 ± 3 
274 ± 10 
227 ± 8 
214 ± 10 
146 ± 8 
P <0.01 
C-20.7D 
p <0.05 
C-17. ID 
p <0.0'5 
C-31.8D 
p <0.001 
(+146.8) 
P <0.001 
(+92.8) 
BO a hov pe r < 
PHOSPHO-
LIPIDS 
136 ± 8 
123 ± 6 
319 ± 11 
268 ± 12 
170 ± 5 
131 ± 6 
P <0.05 
C-09.6D 
P <0.05 
C-16. OD 
P <0.05 
C-22.9D 
p <0.001 
(+134.6) 
P <0.001 
(+25.0) 
: «nI c h a n g a 
TRIGLY-
CERIDES 
125 ± 4 
99 ± 3 
265 ± 1 3 
186 ± 13 
268 ± 12 
229 ± 11 
p <0.001 
C-20.8D 
p <0.01 
C-29. BD 
p <0.05 
C -1 4. 5D 
p <0.001 
(+112.0) 
p <0.001 
(+114.4) 
In g r o u p a aa 
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FIG.4 
PERCENT CHANGE IN PLASMA LIPIDS OF RATS 
TREATED WITH HMG* 
P 
e 
r 
c 
e 
n 
t 
C 
h 
a 
n 
g 
e 
Total Lipids CholGSterol Phosphol ipids'r i lgly(U)( ldo8 
• • Normollpldemic R a t s M ^ Hyper l ip ldemic Rats 
1 1 1 Diabetic Rats 
* values taken from Table 1 
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compared to corresponding controls the amount of HDL was 
considerably higher in rats treated with HMG (Table 2). The 
increase was, however, significant only in diabetic rats 
(54.1%, p <0.05). Although normolipidemic and hyperlipidemic 
rats also showed an increase of 13,2% and 16.4% in the 
amount of HDL, respectively but this was not significant 
(p >O.OS). 
In contrast to HDL, the atherogenic lipoproteins (VLDL+LDL) 
showed a tendency of decrease upon HMG treatment. The 
decrease was significant (p <0.05) in diabetic rats (12.8%) 
as well as in hyperlipidemic rats (17.0%). It is clear from 
Tctbl& 2 that the level of atherogenic lipoproteins in plasma 
is higher in diabetic and hyperlipidemic control groups as 
compared to normolipidemic control group. 
Agarose gel electrophoresis of plasma lipoproteins followed 
by its quantitation through densitometric recording (Fig. 5) 
showed a similar trend on HMG treatment {TaJble 3) . 
Effect of HMG on loLal Protein and Total Lipid Contents of 
Plasma Lipoproteins : The decreasing effect of HMG on plasma 
VLDL+LDL in all the expex'imental groups, witli a parallel 
increase in HDL (Table 2 and Table 3) prompted further 
investigation to find out which fraction of VLDL+LDL and of 
HDL is more affected in treated groups. It was observed that 
in all the three groups, HMG treatment generally decreased 
Table a 
Effect of HMG on Plasma Lipoproteins 
(vciluoo oro moan mg/du ± SE, n=S> 
6 5 
GROUPS * 
I 
II 
III 
IV 
V 
VI 
I 
III 
V 
I 
I 
NLP-C 
NLP-T 
HLP-C 
HLP-T 
DBT-C 
DBT-T 
vs II 
vs IV 
vs VI 
vs III 
vs V 
VLDL + LDL 
153.1 ± 3.2 
146.3 ± 5.6 
167.7 ± 10.6 
139.2 ± 4.4 
197.6 ± 5.6 
172.2 ± 7.6 
NS 
C -4.4. 4D 
p <0.05 
C-17.0D 
p <0.05 
C-12. SD 
NS 
(+09.5) 
p <0.001 
(+29.0) 
HDL 
629.2 ±41.7 
712.0 ± 21.5 
494.2 ± 38.2 
575.2 ± 14.9 
207.8 ±18.7 
320.3 ± 29.6 
p >0.05 
C+13.2D 
p >0.05 
C-VIG. 43 
p <0.05 
C+54. ID 
p <0.05 
(-21.5) 
p <0.001 
(-67.0) 
% V a l u e s In paronthesoo ohov percent change in groups a s 
i, n d l c a l e d . 
NS — Not s i g n i f i c a n t . 
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Fig. S ASCLX-OS& g&L sccxrxs showing &1&C Lroph.or&tic 
pcLtt&m of plasrrux Itpoproteirxs. 
Pook orooa IndLcalo the porcent c o n c e n l r a l l o n a 
of VLDL't-l.DL. (poaJc A> a n d HDL ( p e a k B> i n p l o a m a 
(Values are given in Tahle 3) 
A B A B 
N L P - C NLP -T 
H L f -C H L P . r 
DOT -C DOT -T 
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Table 3 
Effect, of HMG on Electrophoretic Pattern of Plasma Lipoproteins 
(Valuea aro percent c o n c e n t r a t i o n of L ipopro te lna ) 
GROUPS 
I NLP-C 
II NLP-T 
III HLP-C 
IV HLP-T 
V DBT-C 
•VI DBT-T 
VLDL + LDL 
66.6 
59.4 
C-10. 8 D* 
76.2 
47.2 
C-38. 0 ) 
88.4 
71.1 
C-19. e 5 
HDL 
32.9 
40.6 
C +23. 4, y 
23.7 
52.8 
C+122. 8 ) 
10.6 
28.8 
C+166. 7 :> 
>K V a l u e s i n p a r e n t h o o e o s h o w p e r c e n t c h a n g e I n t r e a t e d g r o u p a« 
c o m p a r e d to c o r r e s p o n d i n g c o n t r o l g r o u p . 
6S 
lipid content of VLDL as well as LDL (Table 4). The VLDL 
lipids were significantly lowered in normolipidemic (11.3%), 
hyperlipidemic (20.0%) and diabetic rats (30.5%) but LDL 
lipids were significantly decreased only in hyperlipidemic 
rats to the extent of 49.6% (P <0.01). 
Thoro was a nonsignificant increase in HDL lipids on HMG 
treatment in all the groups. However, the effect was more 
evident in its HDLz and HDL3 subf ractions. There was a 
significant decrease of lipids in HDL9 (39.8%) in 
normolipidemic treated group but in diabetic treated group 
the decrease was not significant. In hyperlipidemic treated 
group a nonsignificant increase in HDLg lipids (23.5%) was 
observed. The HDL2 lipids increased nonsignificantly in 
normolipidemic treated group to the extent of 28.2% but, in 
contrast, it showed a nonsignificant decrease in hyperlipi-
demic as well as in diabetic treated groups in comparison to 
corresponding control groups. 
It is interesting to note that in hyperlipidemic and 
diabetic groups HMG treatment produced a decreasing effect 
on the protein content of VLDL+LDL (Tahle 5). This was 
significant in hyperlipidemic group (p <0.001). VLDL protein 
was decreased significantly in diabetic group (22.2%) after 
HMG administartion. There was a parallel increase in the 
protein content of HDL as well as HDL2 and HDLg but this was 
significant only in normolipidemic treated group. 
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Table- 4 
Effect of HMG on Total Lipid Content of Plasma Lipoproteins 
< V < i l u e a a . r o m e a n m g ^ d l ± S E , n = 5 ) 
GROUPS * 
I NLP-C 
II NLP-T 
III HLP-C 
IV HLP-T 
V DBT-C 
VI DBT-T 
I vs II 
III vs IV 
V vs VI 
I vs III 
I vs V 
VLDL+LDL 
262.9±lT 
199.0±l1i 
617.0130 
440.0±39 
499.0125 
414.7113 
p <0.05 
C -24. 3D 
p <0.01 
C-28.75 
P <0.05 
C-IG. 9D 
p <0.001 
(+134.7) 
p <0.001 
(+89.8) 
VLDL 
157.81 X 
140.11 5 
435.4113 
348.3115 
150.31 9 
104.41 5 
P <0.05 
C-11.3D 
p <0.01 
C-20.OD 
p <0.01 
C-30.5D 
p <0.001 
(+175.9) 
NS 
(-4.7) 
LDL 
105.211^ 
59.012I 
181.3116 
91.4117 
348.8123 
311.3111 
p >0.05 
C-43.9D 
p <0.01 
C -4,9. 6D 
p >0.05 
C-IO.BJ 
P <0.05 
(+72.3) 
p <0.001 
(+231.5) 
HDL 
176.6112 
183.0122 
146.31 5 
156.21 5 
256.6125 
248.5111 
NS 
C +03.GJ 
NS 
C +06. 85 
NS 
C-03. ID 
P >0.05 
(-17.1) 
P <0.05 
(+45.3) 
HDL2 
112.7117 
144.5123 
65.21 9 
55.81 9 
150.3116 
146.2110 
NS 
C +28.2D 
NS 
C -1 4. 4D 
NS 
C-02.7J 
p <0.05 
(-42.1) 
p >0.05 
(+33.4) 
HDL3 
64.0110 
38.51 4 
81.01 5 
100.01 9 
106.4111 
102.31 5 
p <0.05 
C-39.8D 
p >0.05 
C+23.5D 
NS 
C-03. 8D 
p >0.05 
(+26.6) 
p <0.05 
(+66.2) 
t n = 4 
NS = Not a Ignif Ican I 
^ Values Ln parentheseo show percent change i.n groups a a tn(ii.cala3<i. 
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Table 5 
Effect of HMG on Total Protein Content of Plasma Lipoproteins 
<VaLuea aro mean mg/dl ± S C , n - 5> 
GROUPS * 
I , NLP-C 
I I NLP-T 
I I I HLP-C 
IV H L P - T 
V DBT-C 
VI DBT-T 
I v s I I 
I I I v s IV 
V v s VI 
I v s I I I 
I v s V 
VLDL+LDL 
4 . 7 + 0 . 4 ' ' ' 
4 . 7 1 0 . 5 " ^ 
7 . 1 1 0 . 5 
5 . 9 1 0 . 0 1 
6 . 5 + 0 . 2 
5 . 9 ± 0 . 3 
-
-
P < 0 . 0 0 1 
C - 1 6 . 9 D 
NS 
C - 0 9 . 21) 
p < 0 . 0 5 
( + 5 1 . 0 ) 
P < 0 . 0 1 
( + 3 8 . 3 ) 
VLDL 
0 . 7 1 0 . 0 * ' ' 
0 . 6 I 0 . 0 " ' " 
1 . 6 1 0 . 3 
1 . 2 1 0 . 2 
1 . 8 1 0 . 1 
1 . 4 1 0 . 1 
NS 
C - 1 4 . 3D 
P > 0 . 0 5 
C - 2 5 . OD 
P < 0 . 0 5 
C - 2 2 . 2 D 
P < 0 . 0 5 
( + 1 2 8 . 6 ) 
P < 0 . 0 0 1 
( + 1 5 7 . 1 ) 
LDL 
3 . 1 1 0 . 4 ' ' ' 
3 . 4 1 0 . 5 " ' * 
5 . 5 1 0 , 7 
4 . 7 1 0 . 3 
4 . 7 1 0 . 3 
4 . 5 1 0 . 3 
NS 
C + 0 9 . 7 3 
NS 
C - 1 4 . 53 
NS 
C - 0 4 . 2D 
p < 0 . 0 5 
( + 7 7 . 4 ) 
p < 0 . 0 5 
( + 5 1 . 6 ) 
HDL 
6 4 . 5 1 3 . 5 
7 6 . 7 1 3 . 3 
4 7 . 9 1 3 . ^ 
4 8 . 7 1 2 . 1 
4 8 . 5 1 4 . 1 
5 6 . 1 1 2 . 2 
P < 0 . 0 5 
C +22.OD 
NS 
c +01.7-^ 
p > 0 . 0 5 
C +1 5 . 7:i 
p < 0 . 0 1 
( + 2 5 . 7 ) , 
P < 0 . 0 5 
( - 2 4 . 8 ) 
HDL2 
7 . 5 1 3 . 1 
1 5 . 6 1 3 . 4 
1 1 . 7 1 3 . T 
1 2 . 0 1 2 . 5 
9 . 0 1 3 . 3 
1 2 . 3 1 1 . 0 
p < 0 . 0 5 
C + 1 0 8 . 0 D 
NS 
C + 0 2 . 5D 
NS 
C + 3 6 . 7 i 
NS 
( + 5 6 . 0 ) 
NS 
( + 2 0 . 0 ) 
HDLa 
5 6 . 8 1 1 . 2 
6 3 . 0 1 0 . 0 
3 6 . 3 1 1 . t 
3 6 . 5 1 1 . 1 
3 9 . 4 1 0 . 8 
4 3 . 7 1 2 . 4 
p < 0 . 0 0 1 
C + 1 0 . 9 D 
-
-
P > 0 . 0 5 
C + 1 0 . 9 D 
p < 0 . 0 0 1 
( - 3 6 . 0 ) 
p < 0 . 0 0 1 
( - 3 0 . 6 ) 
t n = 4 
NS = Not aLgni.fi.canl 
^ VaLuos in parent hoaoa ahov percent change Cn groupo aa Lt-tdicoileri. 
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Effect of HMG on the Concentrations of Lipids in a Combined 
Fraction of VLDL and LDL : Intraperitoneal administration of 
HMG produced significant changes in the concentration of 
individual lipid components of VLDL+LDL as shown in Table 6. 
As shown in Fig. 6 all the lipid parameters were decreased 
significantly after HMG treatment in normolipidemic and 
hyperlipideraic group except phospholipids in normolipidemic 
group. Though diabetic rats also showed a decreasing trend 
in all lipids but it was significant only for cholesterol 
(28.2%, p <O.OS). It is to be noted that in all the groups 
free (23.5% - 35.3%) as well as ester cholesterol (25.0% -
29.3%) recorded a significant change of considerable 
magnitude. Compared to corresponding control groups, the 
percent composition of lipids in VLDL+LDL did not record 
any significant change on HMG treatment as shown in TaJble 7. 
Although the turbidimetric measurement showed a significant 
decrease in the amount of VLDL+LDL in plasma {Tahli^ 2). 
Effect of HMG on VLUL Lipids : The concentrations of plasma 
VLDL lipids showed considerable changes upon HMG treatment 
to rats. As shown in Tciblo 8, normolipidemic rats 
demonstrated significant lowering of phospholipids (48.4%) 
and triglycerides (23.6%) with a nonsignificant decrease of 
cholesterol concentration (15.8%). Among hyperlipidemic rats 
the concentration of VLDL-cholesterol was decreased more 
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significantly (40.3%, P <0.Ol) than the concentration of 
phospholipids (22.1%)and triglycerides (16.3%, p >0.05). 
Whereas in the case of diabetic rats both cholesterol 
(25.8%) and phospholipids (42.4%) were decreased more 
significantly (p <0.01) than the triglycerides (11.3%, 
p >0.OS) in treated group as compared to control group (Fig. 
7) . From the data given in Ta.b>le 8, it can also be seen 
that the concentration of all the lipids is significantly 
raised in hyperlipideraic and diabetic control groups as 
compared to normolipidemic control group. 
In order to assess the efficacy of HMG in lowering lipid 
parameters of VLDL, VLDL-cholesterol : VLDL-triglyceride 
ratio was calculated from the data given in Table 8. It 
appears that HMG treatment decreases this ratio in 
hyperlipideraic and diabetic rats to the extent of 29.6% and 
18.5% respectively (p >0.05) as shown in TcihlG 9. In 
normolipidemic rats the ratio was not much altered. This may 
mean that mechanism of hypolipidemic action of HMG is 
dependent on the physiological status of the animals. This 
will be commended more in discussion. 
Tablo to shows tho percent lipid composition of VLUL. In 
case of hyperlipidemic group tlie composition of VLDL was not 
much affected after HMG treatment. Although significant 
lowering of phospholipids in normolipidemic (8.2%) and 
diabetic (6.6%) groups was observed. Diabetic HMG tz-eated 
Ta.tile' G 
Effect of HMG on VLDL + LDL Lipids 
(VaLueo aro moan mg/dl ± SC,n = 5) 
73 
GROUPS * 
I 
II 
III 
IV 
V 
VI 
I 
I I I 
V 
I 
I 
NLP-C 
NLP-T 
HLP-C 
HLP-T 
DBT-C 
DBT-T 
vs II 
vs IV 
vs VI 
vs III 
vs V 
TOTAL 
CHOLE-
STEROL 
75.0± 4 
54.0± 4 
178.0±10 
130.0± 3 
101.2± 6 
72.7± 7 
p <0.01 
C-28.05 
p <0.01 
C-26.9D 
P <0.05 
C-28.2D 
p <0.001 
(+137.3) 
p <0.01 
(+34.9) 
FREE 
CHOLE-
STEROL 
17.0± 1 
13.0± 1 
34.0± 2 
22.0+ 3 
16.7±0.8 
11.6± 1 
p <0.05 
C-23. 55 
p <0.05 
C-35. 33 
p <0.01 
C-30. S5 
p <0.001 
(+100.0) 
NS 
(-01.8) 
ESTER 
CHOLE-
STEROL 
58.0± 4 
41.0± 4 
144.0± 9 
108.0± 3 
84.5± 6 
61.1± 6 
p <0.05 
C-29. 35 
p <0.01 
C-25.05 
p <0.05 
C-2r.75 
p <0.001 
(+148.3) 
p <0.01 
(+45.7) 
PHOSPHO-
LIPIDS 
64.0± 6 
57.0± 2 
126.0± 3 
101.0± 6 
102.5±lS 
70.2±lS 
NS 
C-10. 95 
p <0.01 
C-19.85 
p >0.05 
C-31. S5 
p <0,001 
(+96.9) 
P <0.05 
(+60.1) 
TRIGLY-
CERIDES 
99.0± 3 
73.0± 3 
226.0± 9 
156.0110 
202.51 T 
188.41 % 
p <0.001 
C -2G. 35 
p <0.001 
C-31. 05 
p >0.05 
C-07.05 
p <0.001 
(+128.3) 
P <0.001 
(+104.5) 
TOTAL 
238.0 
184.0 
530.0 
387.0 
406.0 
331.0 
C-22.75 
C-27.05 
C-IO. 55 
(+122.7) 
(+70.6) 
•f n = •* 
N S = Not a v gni f \. c an t 
^ V a l u e s In paronlh<»a«a s h o w p o r c e n l c h a n g o i.n g r o u p e a a i n d i c n t o d . 
FIO. 6 
PERCENT CHANGE IN VLDL • LDL LIPIDS 
OF RATS TREATED WITH HMQ« 
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P 
e 
r 
G 
6 
n 
t 
C 
h 
a 
n 
g 
e 
Total Cholea. Free Cholee. Ester Cholea. Phoapholipids Triglycerides 
H I Normoilpldemic Rats tiM^ Hyperllpldemic Rats 
lUi] Diabetic Rats I 
• values taken from Table 6 
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Table 7 
Effect of HMG on Lipid Composition of VLDL + LDL 
(Valuoo are oxpreeoed a.a moan M of Lolal lipid ± SC ) 
GROUPS 
I NLP-G 
II NLP-T 
III HLP-C 
IV HLP-T 
V DBT-C 
VI DBT-T 
I vs II 
III vs IV 
V vs VI 
I vs III 
I vs V 
CHOLESTEROL 
31.5 ± 1.3 
29.3 ± 1.3 
33.5 ± 1.3 
33.8 ± 1.2 
25.0 ± 1.7 
21.9 ±1.9 
NS 
NS 
NS 
NS 
P <0.05 
PHOSPHOLIPIDS 
26.9 i i:'. 6 
31.0 ± 1.1 
23.8 ± 0.5 
26.2 ± 1.1 
25.0 ± 2.3 
21.2 ± 2.3 
P >0.05 
p >0.05 
NS 
p >0.05 
NS 
TRIGLYCERIDES 
41.6+1.0 
39.7 ± 0.4 
42.7 ±1.1 
40.4 ± 1.1 
50.0 ± 1.1 
56.9 ± 1.7 
p >0.05 
p >0.05 
P <0.05 
NS 
P <0.001 
* Calculated from Table 6. 
NS = Not s C gn i. f i c an I . 
Table 8 
Effect of HMG on VLDL Lipids 
(Valuos aro m«an mg/dl ± SE, n = 5> 
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GROUPS * 
I NLP-C 
II NLP-T 
III HLP-C 
IV HLP-T 
V DBT-C 
VI DBT-T 
I vs II 
III vs IV 
V vs VI 
I vs III 
I vs -V 
CHOLESTEROL 
19.6 ± 2.9 
16.5 ± 1.4. 
65.3 ± 4.1 
39.0 ± 5.7 
33.0 ± 1.7 
24.5 ± 0.8 
MS 
C-15. 4,D 
p <0.01 
C-40. 3) 
p <0.01 
C-25.8> 
p <0.001 
(+233.2) 
p <0.01 
(+68.4) 
PHOSPHOLIPIDS 
46.5 ± 5.0 
24.0 ± 1.8 
25.3 ± 2.0 
19.7 ± 2.6 
51.2 ± 3.2*^ 
29.5 ± 3.2'*' 
p <0.01 
C-48. S:) 
p >0.05 
C-22.1) 
p <0.01 
C-42.il) 
p <0.01 
(-45.6) 
NS 
(+10.1) 
TRIGLYCERIDES 
82.2 ± 3.9 
62.8 ± 1.4 
122.8 ±11.5 
102.8 ± 5 . 4 
123.2 ± 5.3''' 
109.3 ±4.1''' 
p <0.01 
C-23. 6) 
p >0.05 
C-16. 3) 
p >0.05 
C-11.3) 
p <0.05 
(+49.4) 
p <0.001 
(+49.9) 
TOTAL 
148.3 
103.3 
213.4 
161.5 
207.4 
163.3 
C-30. 33 
C -24. 3) 
C-21. 2) 
p <0.01 
(+43.9) 
p <0.001 
(+39.8) 
1" n = <i 
^ V a l u « a in p a r o n l h ^ s e a ahov p o r c « n l c h a n g e In g r o u p s a a i.t^dlicale<i. 
N S = Nol aignificaiil. 
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FIG. 7 
PERCENT CHANGE IN VLDL LIPIDS OF RATS 
TREATED WITH HMQ» 
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Table- 9 
E f f e c t of HMG on C l i o l e s t e r o l : T r i g l y c e r i d e R a t i o of VLDL 
( V a l u e s o i r o m o a n ± S E > * 
GROUPS** 
I NLP-C 
II NLP-T 
III HLP-C ' 
IV HLP-T 
V DBT-C 
VI DBT-T 
I vs • II 
III vs IV 
V vs VI 
I vs III 
I vs V 
VLDL - Cholesterol 
VLDL - Triglyceride 
0.24 ± 0.03 
0.26 ± 0.03 
0.54 ± 0.04 
0.38 ± 0.06 
0.27 ± 0.02 
0.22 ± 0.01 
NS 
C+08. 3D 
p >0.05 
C -29. 6:> 
p >0.05 
c-ia.5:> 
p <0.00l 
(+125.0) 
NS 
(+12.5) 
* Valuta calcuLaled from Tdhte 8 
i^ ValuAS In paronthesAS shov porconl change in groups ao 
i. nd i o o, t od 
N S = Not c L g n i f i c a n t 
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Tabli^ iO 
Effect of HMG on Lipid Composition of VLDL 
< V a l u o a a r o e x p r o a e e d as m o a n M of lolal I i. p i. d ± S E > 
GROUPS 
I NLP-C 
II NLP-T 
III HLP-C 
IV HLP-T 
V DBT-C 
VI DBT-T 
I vs II 
III vs IV 
V vs VI 
I vs III 
I vs V 
CHOLESTEROL 
13.2 ± 1.4 
16.0 ±1.4 
30.6 ± 1.4 
24.0 ± 2.6 
15.9 ± 0.9 
15.0 ± 0.4 
p >0.05 
p >0.05 
NS 
p <0,001 
P >0.05 
PHOSPHOLIPIDS 
31.4 ±1.8 
23.2 ± 1.5 
11.9 ± 0.7 
12.2 ± 0.9 
24.7 ± 1.0 
18.1 ± 1.0 
P <0.01 
NS 
P <0.01 
p <0.001 
p <0.05 
TRIGLYCERIDES 
55.4 ± 2.5 
60.8 ± 1.4 
57.5 ± 1.5 
63.7 ± 2.7 
59.4 ± 1.4 
66.9 ± 0.9 
p >0.05 
P >0.05 
P <0.01 
NS 
NS 
* C a l c u l a t e d from Ta.blG' 8. 
N S = Not a i. gni f i c a n I . 
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rats showed increased percentage of triglycerides in VLDL. 
Effect of HMG on LDL Lipids : The effect of HMG on the 
concentrations of LDL lipids is shown in Table 11. The 
values of LDL lipids were calculated indirectly by 
subtracting the values of VLDL lipids from the values of 
VLDL+LDL lipids. In normolipidemic group, after IIMG 
treatment, concentrations of total cholesterol and trigly-
cerides decreased significantly to the extent of 33.6% and 
40.3%, respectively, but concentration of phospholipids 
showed a nonsignificant increase of 37.5% (Fig. 8). Among 
hyperlipidemic rats, treatment with HMG caused significant 
lowering of phospholipids (19.4%) and triglycerides (51.9%). 
Although LDL-cholesterol was also reduced considerably 
(19.4%) but it did not reach statistical significance 
(p >O.OS). In case of diabetic gi'oup, HMG treatment did not 
affect LDL-triglyceride concentration, howevez", it lowered 
LDL-cholesterol significantly (29.2%, p <0.05) and phos-
pholipids nonsignificantly (20.8%). From the data shown 
in Tahle ii it is also clear that in hyperlipidemic control 
rats all the lipid parameters of LDL were significantly 
raised in comparison to normolipidemic control rats. 
Diabetic rats also showed elevated levels of LDL lipids, 
more significantly LDL-triglycerides. 
The percent lipid composition of LDL (calculated from tlie 
Table 11 
Effect of HMG or. LDL Lipids 
(Valuos aro moan mg/dl ± SE, n = 5> 
ei 
GROUPS * 
I 
II 
III 
IV 
V 
VI 
I 
III 
V 
I 
I 
NLP-C 
NLP-T 
HLP-C 
HLP-T 
DBT-C 
DBT-T 
vs II 
vs IV 
V3 VI 
vs III 
V3 V 
CHOEiESTEROL 
53.5 ± 4.5 
35.5 ± 3.5 
112.3 ±10.0 
90.9 ± 4.6 
68.1 ± 5.3 
48.2 ± 6.7 
p <0.05 
C-33. 63 
p >0.05 
C-19.0) 
p <0.05 
C-29.2) 
p <0.001 
(+109.9) 
p >0.05 
(+27.3) 
PHOSPHOLIPIDS 
23.7 ± 4.5 
32.6 ± 3.6 
100.0 ± 4 . 0 
80.6 ± 6.0 
51.3 ±12.5''" 
40.6 ±10.0"*" 
p >0.05 
C437.5> 
p <0.05 
C-19. 4D 
NS 
C-20.8) 
p <0.001 
(+321.9) 
p >0.05 
(+116.4) 
TRIGLYCERIDES 
17.1 ± 1.3 
10.2 ± 2.0 
103.0 ± 9.3 
49.5 ± 5.8 
79.2 ± 6.5''" 
79.1 ± 7.9"'' 
p <0.05 
C-40.3) 
p <0.01 
C-S1.9) 
-
— 
p <0.001 
(+502.3) 
p <0.001 
(+363.2) 
TOTAL 
94.3 
78.3 
314.5 
221.0 
198.7 
167.9 
C-17.0) 
C-29.73 
C-15. 53 
p <0.001 
(+233.5) 
p <0.001 
(+110.7) 
t n = 4 
% V a l u o s i n p a r « n t h e s » s a h o v p o r c « n l c h a n g e i n g r o u p i 
t^ S = Nol signiTicanL. 
a a i n d i c c i l < » < i . 
ea 
FIG. 8 
PERCENT CHANGE IN LDL LIPIDS OF RATS 
TREATED WITH HMG* 
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* 
Table 12 
Effect of HMG on Lipid Composition of LDL 
< V a l u o o a. r o e x p r e e a e d a s m e c i n M o f l o l a l l i p i d ± S E ) 
GROUPS 
I 
II 
III 
IV 
V 
VI 
I 
III 
V 
I 
I 
NLP-C 
NLP-T 
HLP-C 
HLP-T 
DBT-C 
DBT-T 
vs II 
vs IV 
vs VI 
vs III 
vs V 
CHOLESTEROL 
56.6 ± 3.6 
45.4 ± 0.5 
35.6 ± 2.0 
41.2 ± 0.6 
34.4 ± 2.6 
28.7 ± 3.8 
p <0.05 
p <0.05 
NS 
p <0.001 
P <0.01 
PHOSPHOLIPIDS 
25.0 ± 3.6 
41.8 ±1.4 
32.0 ±1.0 
36.6 ± 1.6 
25.4 ± 4.5 
24.0 ± 4.1 
P <0.01 
p <0.05 
NS 
P >0.05 
NS 
TRIGLYCERIDES 
18.4 ± 1.7 
12.8 ±1.2 
32.3 ± 1.8 
22.2 ±1.8 
40.1 ± 2.7 
47.2 ± 3.2 
P <0.05 
P <0.01 
P >0.05 
P <0.001 
P <0.001 
* G o - l c u l a l o d f r o m Tab I e 1 i 
N S ~ N o l o l g n l f l c o i n l . 
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data given in Tat>l& 11) is .-ihowri in TcttilG la. SiKnificant 
alteration in the lipid composition of LDL was noticed in 
normolipideinic and hyperlipidemic groups treated with HMG. 
Diabetic rats did not show any significant change in LDL 
composition in response to HMG treatment. The percentage of 
total cholesterol in LDL was decreased in normolipidemic but 
increased in hyperlipidemic group treated with HMG as 
compared to corresponding controls. Phospholipid content was 
found to be elevated both in normolipidemic and hyper-
lipidemic groups but remained unchanged in diabetic group in 
response to HMG treatment. On the other hand percentage of 
triglyceride in LDL was decreased in normolipidemic and 
hyperlipidemic groups but increased in diabetic group after 
treatment with HMG. 
Effect of HMG on HDL Lipids : Tciblo 13 shows the effect of 
HMG administration on HDL lipids. The concentration of 
HDL-cholesterol was increased in response to HMG treatment 
considerably and significantly (p <0.05) in hyperlipidemic 
(38.5%) and diabetic (48.0%) rats. The increase in HDL-
cholesterol (13.6%) was not significant among normolipid-
emic rats. In all the three groups HDL-triglyceride 
concentration was significantly lowered upon HMG treatment 
(39.6%-60.0%). However, it did not produce any significant 
effect on HDL-phospholipids (Fig. 9). Table 14 shows the 
Table 13 
Effect of HMG on HDL Lipids 
< V c s . l a e a o i r « m o a n m g y ' d l ± SK , n = 5 ) 
35 
GROUPS * 
I 
II 
III 
IV 
V 
VI 
I 
III 
V 
I 
I 
NLP-C 
NLP-T 
HLP-C 
HLP-T 
DBT-C 
DBT-T 
vs II 
vs IV 
vs VI 
vs III 
vs V 
CHOLESTEROL 
67.7 ± 7,3 
76.9 ± 9.9 
41.5 ± 4.2 
57.5 ±2.8 
102.5 ±4.1 
153.2 ±21.6 
NS 
C+13.6D 
p <0.05 
C+38.5D 
p <0.05 
C+40.0D 
p <0.05 
(-38.7) 
p <0.01 
(+51.4) 
PHOSPHOLIPIDS 
180.4 ± 8.3 
167.9 ±10.6 
99.9 ± 4.5 
107.9 ± 3.8 
145.4 ± 5.8 
147.8 ± 3.5 
NS 
C-06.9D 
p >0.05 
C +08. 03 
NS 
C +01. 6D 
p <0.001 
(-80.5) 
p <0.01 
(-19.4) 
TRIGLYCERIDES 
39.6 ± 1.9 
23.9 ± 2.2 
31.6 ± 2.4 
12.4 ± 1 . 4 
43.4 ± 4.8 
19.8 ± 1.8 
p <0.001 
C-39.6D 
p <0.001 
C-GO. OD 
p <0.01 
C-54. OD 
P <0.05 
(-20.2) 
NS 
(+09.5) 
TOTAL 
287.7 
268.7 
173.0 
177.7 
291.1 
320.8 
C-06.63 
C +02.7D 
C+10.2D 
p <0.001 
(-39.8) 
NS 
(+01.2) 
^ V a l u e s i n p a r e n l h o o o o a h o v p o r c o n l c h a n r / o i .n ( / r o u p o a o ir i<- i i .cr i i t i<l 
N S = N o l • ». g n l . r I c a n l . . 
QG 
FIG. 9 
PERCENT CHANGE IN HDL LIPIDS OF RATS 
TREATED WITH HMG* 
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TabiG 14 
Effect of HMG on HDL^ Lipids 
<Valu«»o a r © m o a n m g / d l i SK , n S ) 
GROUPS * 
I 
II 
III 
IV 
V 
VI 
I 
III 
V 
I 
I 
^ 
NLP-C 
NLP-T 
HLP-G 
HLP-T 
DBT-C 
DBT-T 
vs II 
vs IV 
vs VI 
vs III 
vs V 
CHOLESTEROL 
54.5 ± 6.7 
61.8 ± 8.8 
18.3 ± 2.8 
27.4 ± 6.6 
36.4 ± 7.1 
80.7 ±11.7 
NS 
C+13.4,D 
p >0.05 
C +49.70 
p <0.05 
C +1 El. 7D 
p <0.001 
(-66.4) 
p >0.05 
(-33.2) 
PHOSPHOLIPIDS 
55.5 ± 8.5 
58.8 ±19.8 
47.3 ± 3.4 
56.4 ± 5.0 
12.1 ± 1.9 
50.5 ± 2.9 
NS 
C +05.9D 
P >0.05 
c+19. a) 
p <0.00i 
C +31 7. 33 
NS 
(-14.8) 
p <0.01 
(-78.2) 
TRIGLYCERIDES 
20.4 ± 2.1 
8.5 ± 2.1 
20.4 ± 1.9 
7.2 ± 1.4 
35.4 ± 4.2 
14.2 ± 1.0 
P <0.01 
C-58.33 
p <0.001 
C -Gd. 73 
p <0.01 
C-59. 93 
NS 
-
P <0.05 
(+73.5) 
TOTAL 
130.3 
129.0 
86.0 
91.0 
83.9 
145.5 
C-01.03 
C +05.83 
C +73. 43 
p <0.01 
(-34.0) 
p <0.01 
(-35.6) 
5K V o i L u o a i. n p a . r « n t h o o o o s h o w p o r c o n l c h a n g e i. n g r o u p o a.o I n d L c c i L o d . 
N S = N o t o L g n l f l c a n L . 
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effect of HMG treatment on HDLz lipids. HDLz-cholesterol as 
well as HDLa-phospholipids increased in treated groups as 
compared to corresponding controls as also shown in Fig. lO. 
The increase was more significant in diabetic group than 
in the hyperlipidemic group but it was not significant in 
normolipidemic group. In contrast,triglyceride concentration 
was decreased significantly (58.3%-64.7%) in all the groups 
in response to HMG administration. The concentrations of 
HDLa lipids are shown in Tahle 15. HMG treatment decreased 
phospholipid and triglyceride concentrations of HDLg but 
increased HDLg-cholesterol as shown in Fig. 11. The increase 
in cholesterol was not significant in any of the group. 
However, decrease in phospholipids was significant in 
diabetic group (27.0%) and the decrease in triglycerides was 
significant in hyperlipidemic group (54.5%). 
To compare the effect of HMG on HDL subfractions, the ratio 
of HDLz-cholesterol to HDLa-cholesterol was calculated from 
the values reported in Tat>l& 14 and Tabl& 15. As shown in 
Table 16, HMG administration produced different responses in 
normolipidemic, hyperlipidemic and diabetic rats. This ratio 
was decreased (11.6%) in normolipidemic rats but increased 
(22.4%) in hyperlipidemic rats upon HMG treatment. These 
alterations were, however, not significant. The effect was 
more pronounced in diabetic rats where the treated group 
showed significantly increased ratio of HDLz-cholesterol to 
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FIG. 10 
PERCENT CHANGE IN HDL2 LIPIDS OF RATS 
TREATED WITH HMG* 
400 
P 
e 
r 
c 
e 
n 
t 
C 
h 
a 
n 
g 
e 
300 -
200 
100 
- 1 0 0 
Cholesterol Phospholipids Triglycerides 
H i Normollpldemlc R a t ^ ^ Hyperlipidemlc Rats 
m i Diabetic Rats 
values taken from Table 14 
Table 15 
Effect of HMG on HDLg Lipids 
( V a l u e s aro m e a n m g / d l ± S E , n = 5) 
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GROUPS * 
I 
I I 
I I I 
IV 
V 
VI 
I 
I I I 
V 
I 
I 
NLP-C 
NLP-T 
HLP-C 
HLP-T 
DBT-C 
DBT-T 
v s I I 
v s IV 
v s VI 
v s H I 
V3 V 
CHOLESTEROL 
1 3 . 2 ± 2 . 6 
1 5 . 1 i 1 . 6 
2 3 . 2 ± 4 . 2 
3 0 . 1 ± 6 . 4 
6 6 . 1 ± 8 . 9 
7 1 . 4 ± 6 . 2 
NS 
C +1 4,. 41) 
NS 
C + 2 9 . 7 D 
NS 
C +08.OD 
p > 0 . 0 5 
( + 7 5 . 7 ) 
p < 0 . 0 0 1 
( + 4 0 0 . 7 ) 
PHOSPHOLIPIDS 
1 2 4 . 9 ± 5 . 4 
1 0 9 . 1 ± 6 . 5 
5 2 . 7 ± 2 . 9 
5 1 . 3 ± 3 . 2 
1 3 3 . 3 ± 5 . 2 
9 7 . 3 ± 5 . 1 
p > 0 . 0 5 
C - 1 2 . 63 
NS 
C - 0 2 . GD 
p < 0 . 0 1 
C - 2 7 . O D 
p < 0 . 0 0 1 
( - 5 7 . 8 ) 
NS 
( + 0 6 . 7 ) 
TRIGLYCERIDES 
1 9 . 2 ± 2 . 3 
1 5 . 5 ± 2 . 7 
1 1 . 2 ± 1 . 2 
5 . 1 ± 1 , 6 
8 . 0 ± 0 . 8 
5 . 6 ± 1 . 4 
NS 
C - 1 9 . 33 
p < 0 . 0 5 
C - 5 4 . 5 3 
p > 0 . 0 5 
C - 3 0 . 03 
P < 0 . 0 5 
( - 4 1 . 7 ) 
p < 0 . 0 1 
( - 5 8 . 3 ) 
TOTAL 
1 5 7 . 2 
1 3 9 . 7 
87 . 0 
8 6 . 6 
2 0 7 . 3 
1 7 5 . 2 
C - 1 1 . 1 3 
-
C - 1 5 . 53 
( - 4 4 . 6 ) 
( + 3 1 . 9 ) 
^ V a l u o o I n p a r o n l h o u o o o h o w p e r c e n t c h i a n g o t n g r o u p o <xo i ixXi a cxl wl . 
NS = N o t a I 9 n L f t c a n L . 
9i 
FIG. 11 
PERCENT CHANGE IN HDL3 LIPIDS OF RATS 
TREATED WITH HMG* 
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TablG IG 
Effect of HMG on HDL2-Cholesterol : HDL3-Cholesterol Ratio 
* (VaLuoB .are mean Z SC) 
GROUPS*^ 
I NLP-C 
II NLP-T 
III HLP-C 
IV HLP-T 
V DBT-C 
VI DBT-T 
I vs II 
III vs IV 
V vs VI 
I vs III 
I vs V 
HDL2 - Cholesterol 
HDL3 - Cholesterol 
4.67 ± 0.88 
4.13 ± 0.51 
0.98 ± 0.33 
1.20 ± 0.37 
0.56 ± 0.09 
1.10 ± 0.17 
NS 
C-11.6D 
NS 
C +22. dD 
P <0.05 
C +96. 4-D 
p <0.01 
(-79.0) 
p <0.01 
(-88.0) 
* V a l u o s c a l c u l a t e d from Table 14 and TciblG 15 
iX V a l u e s in p a r o n l h e o e a s h o w percer-<l c h a n g e in g r o u p s ao 
x. nd I c a L ed 
N S = Not • i g n C f l e a n t 
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HDLg-cholesterol (96.4%, p <0.05). From this data it also 
appears that the ratio is decreased significantly under 
conditions of hyperlipidemia and diabetes when compared with 
normal rats (p <0.01). 
The percent composition of HDL, HDLz and HDLg are shown in 
Table 17, 13 and 19 respectively. The amount of major lipid 
components (cholesterol, phospholipids and triglycerides) 
was calculated as percentage of total lipids from the data 
reported in Tat>le 13, 14 and 15 respectively. The effect of 
HMG in changing the composition of HDL particles seems to be 
similar in all the three groups, although it differed in 
magnitude. Taken together with the data from Table 13, 14 
and 15, it indicates that the major effect of HMG 
administration (i.p-) appears to be the reduction in 
triglyceride content of HDL (Fig. 9) as well as HDL 
subfractions (Fig. lO, Fig. 11) with a parallel rise of the 
cholesterol content. The increase in the percentage of 
cholesterol in HDL was significant among hyperlipidemic (p 
<O.OS) and diabetic rats (p <0.01) but this did not reach 
statistical significance in HDL2 subfraction (Table 18). 
However, percentage of cholesterol in HDL3 was significantly 
raised (p <0.05) in diabetic group after HMG treatment 
{TcLble 19). The percentage of phospholipids in HDL particles 
remained unaltered by HMG treatment {Tahle 17) but 
differences were observed when individual subfractions were 
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* 
TablG 17 
Effect of HMG on Lipid Composition of HDL 
( V a l u o a aro e x p r o a o o d as m o a n M of Lolal lipid ± SIC) 
GROUPS 
I 
II 
III 
IV 
V 
VI 
I 
III 
V 
I 
I 
NLP-C 
NLP-T 
HLP-C 
HLP-T 
DBT-C 
DBT-T 
vs II 
vs IV 
vs VI 
vs III 
vs V 
CHOLESTEROL 
23.4 ± 2.3 
28.3 ± 2.7 
24.0 ± 2.2 
32.3 ± 1.2 
35.3 ± 1.7 
47.2 ± 3.0 
NS 
P <0.05 
P <0.01 
NS 
p <0.01 
PHOSPHOLIPIDS 
62.7 ± 1.8 
62.8 ± 2.6 
57.8 ± 2.0 
60.7 ± 1.1 
49.8 ± 1.5 
46.6 ± 3.0 
NS 
NS 
NS 
p >0.05 
p <0.001 
TRIGLYCERIDES 
13.8 ± 0.6 
8.9 ± 0.6 
18.3 ± 1.1 
6.9 '± 0.5 
14.8 ± 1.5 
6.1 ± 0.5 
p <0.001 
p <0.'001 
p <0.001 
P <0.01 
NS 
* C a l c u l a t o d from TaJb le 13. 
N S = Not a i g n l f l e a n t . 
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* 
Table 18 
E f f e c t of IIMG on L i p i d C o m p o s i t i o n of HDL^ 
< V a l u o s <xr o oxproaaod as m e a n H of loLal lipid ± S E > 
GROUPS 
I NLP-C 
II NLP-T 
III HLP-C 
IV HLP-T 
V DBT-C 
VI DBT-T 
I V3 II 
III vs IV 
V vs VI 
I vs III 
I vs V 
CHOLESTEROL 
41.9 ± 4.0 
47.6 ± 2.4 
21.2 ± 2.7 
28.9 ± 3.9 
43.3 ± 5.3 
54.5 ± 3.4 
NS 
P >0.05 
p >0.05 
p <0.01 
NS 
PHOSPHOLIPIDS 
42.7 ± 3.5 
46.2 ± 3.4 
54.7 ± 1.8 
62.4 ± 2.6 
14.7 ± 2.6 
35.7 ± 3.2 
NS 
p <0.05 
p <0.001 
p <0.05 
p <0.001 
TRIGLYCERIDES 
15.4 ± 1.1 
6.2 ±1.1 
• 24.1 ± 2.3 
8.7 ± 2.2 
42.0 ± 3.7 
9.9 ± 0.5 
p <0.001 
P <0.01 
p <0.001 
P <0.01 
p <0.001 
* C a l c u l a t « d f r o m TabIG 14. 
N S = Nol a i. gn I f i c an I . 
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* 
Ta.bl& 19 
Effect of HMG on Lipid Composition of HDL3 
( V a l u e a are e x p r o o a e d aa m e a n M of lolal lipid h SIL > 
GROUPS 
I NLP-C 
II NLP-T 
III HLP-C 
IV HLP-T 
V DBT-C 
VI DBT-T 
I vs II 
III vs IV 
V vs VI 
I vs III 
I vs V 
CHOLESTEROL 
8.2 ± 1.4 
11.0 ± 1.2 
25.9 ± 3.0 
33.4 ± 4.0 
31.6 ± 2.2 
41 .2 ± 2.6 
P >0.05 
p >0.05 
P <0.05 
P <0.001 
P <0.001 
PHOSPHOLIPIDS 
79.6 ± 1.0 
78.0 ± 0.8 
60.8 ± 2.1 
60.2 ± 3.1 
64.4 ± 2.0 
55.6 ± 2.4 
NS 
NS 
p <0.05 
P <0.001 
P <0.001 
TRIGLYCERIDES 
12.1 ± 1.2 
10.9 ± 1.6 
13.2 ± 1.9 
6.4 ± 1.9 
4.0 ± 0.6 
3.2 ± 0.8 
NS 
P <0.05 
NS 
NS 
P <0.001 
* C a l c u l a t e d from T a b l e 15. 
N S = Not B i. gn i. f V, can I . 
97 
analyzed. HMG treatment caused an increase in tVie percentage 
of phospholipids in HDL2 {Table- 18). This was more 
significant in diabetic group (p <0.001) than in hyper-
lipidernic group (p <0. OG). On the other hand, in HDLa 
particles {Tabl& 19) phospholipid content remained either 
unchanged (hyperlipideraic group) or decreased (normolipi-
demic and diabetic groups) upon HMG treatment. 
Effect of HMG on tlie Indicators of Atherogenic Risk : The 
ratios of total plasma cholesterol • HDL-cholesterol and 
VLDL + LDL-cholesterol : HDL-cholesterol are con.'jidered arj 
indicators of atherogenic risk (Castelli. 1984; Miller GL 
al, 1982), As shown in Tatde 20, these ratios were 
significantly reduced upon HMG treatment in normolipidemic, 
hyperlipideraic and diabetic rats. Compared to corresponding 
controls, the magnitude of reduction in the two ratios was 
approximately same. Moreover, the lowering of these ratios 
was more significant in hyperlipideraic and diabetic groups 
(p <0. OOl) than in the normolipidemic group (p <0.05). It 
also appears that the average values of these ratios are 
significantly higher in diet induced hyperlipidemia (p 
<0.OOl) and the effect of HMG is more pronounced in 
hyperlipideraic and diabetic rats. 
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Ta-bl& ao 
Effect of HMG on Indicators of Atherogenic Risk 
( V a l u e s a r e m e a n i: S C , n 5 > 
1 
GROUPS * 
I NLP-C 
II NLP-T 
III HLP-C 
IV HLP-T 
V DBT-C 
VI DBT-T 
I vs II 
III vs IV 
V vs VI 
I vs III 
I vs V 
* 
Total Plasma Cholesterol 
HDL - Cholesterol 
1.7 ± 0.16 
1.2 ± 0.15 
6.8 ± 0.53 
3.9 ± 0.11 
2.1 ± 0.07 
1.0 ± 0.17 
P <0.05 
C -29. 4D 
p <0.001 
C-42.G3 
p <0.001 
C-52. 4> 
p <0.001 
(+300.0) 
P <0.05 
(+23.5) 
VLDL+LDL - Cholesterol 
HDL - Cholesterol 
1.15 ± 0.10 
0.74 ± 0.10 
4.40 ± 0.33 
2.28 ± 0.11 
0.98 ± 0.07 
0.49 ± 0.04 
p <0.05 
C-35. GD 
p <0.001 
C-48.2D 
p <0.001 
C-50. 03 
p <0.001 
(+282.6) 
p >0.05 
(-14.8) 
<t V a l u o o a r e o o l c u l a l o d from Tab IG I , Tab IG 6 G Tab IG i 3. 
'^ V a l u e a i.n p a t a n l h e a e a a h o v p e r c e n t c h a n g e i.n g r o u p s o.a 
Indicated. 
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Effect of HMG on Apolipoproteins of Different Lipoprotein 
Fractions : Apolipoprotein patterns as obtained on SDS-
polyacrylaralde gel electrophoresis are shown in Fig. 12-15. 
The lipoprotein samples of control and treated rats were 
electrophoresced under identical conditions. Since we did 
not have the facility to isolate and identify pure apolipo-
proteins from rat plasma, the electrophoretic pattern of 
apolipoproteins was compared with the pattern obtained by 
Connelly and Kuk.qis (1982) and Wilcox GL al (1981). In VLDL+ 
LDL fractions of normolipidemic rats (Fig. 12) a slight 
increase in apoA-I was associated with a slight decrease in 
apoE in treated rats. However, in hyperlipidemic and 
diabetic treated rats increase in apoC-II and apoC-III as 
well as apoA-I proteins was seen. 
The apoprotein profile of HDL fractions exhibited apoE and 
apoA-I as major and apoA-IV and apoA-II as minor bands (Fig. 
13). In normolipidemic rats HMG treatment resulted in a 
decrease of apoE only. However, a decrease of apoA-II in 
hyperlipidemic rats and an increase of apoA-I and apoE in 
diabetic treated rats was observed (Fig. 13). In contrast to 
HDL, electrophoresis of HDL subfractions provided a more 
clear information about the effect of HMG on apolipo-
proteins. ApoE and apoA-I of HDLz were increased in both 
hyperlipidemic and diabetic treated rats but decreased in 
normolipidemic rats. ApoA-II of HDL2 was decreased in 
lOO 
Fig. 12 Com.pa.rt son. of th& ctpo lipoprotein profile of 
ploLsma. VLDL + LDL fraction from control and 
HMG treated rats of different groups 
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normolipidemic, remained unaffected in hyperlipidemic but 
increased in diabetic group upon HMG administration (Fig-
14). Apolipoproteins of HDL3 subfraction did not exhibit any 
change in normolipidemic and hyperlipidemic groups but in 
diabetic group HMG treatment resulted in the increase of 
apoE and a decrease of apoA-I in HDLg subfraction (Fig. 15). 
Effect of HMG on the Activity of Tissue Lipases : The activ-
ity of lipase enzyme was measured in liver and heart 
homogenates. As reported in Table 2i , rats in the treated 
groups showed a significantly low activity of myocardial 
lipase as compared to control rats. The decrease was more 
marked in hyperlipidemic rats (45.2%) than in the 
normolipidemic rats (35.8%). It correlates well V7ith 
significant increase of hepatic lipase activity in both 
hyperlipidemic (156.4%) and normolipidemic (36.8%) HMG 
treated groups in comparison to corresponding control groups. 
Effect of HMG on the Activity of Post-tiepar In F'lasma Lipases 
CHTGL and LPLD : Since HMG treatment resulted in alteration 
of lipoprotein lipids, it was logical to conclude that tlie 
hypolipidemic action of HMG is related to its interference 
with lipoprotein metabolism. Therefore, it was desirable to 
investigate the effect of HMG on hepatic triglyceride lipase 
(HTGL) and lipoprotein lipase (LPL) in post-heparih plasma 
iOG 
TahlG 21 
Effect of HMG on t^ le Activity of Tissue Lipases 
<Va . lue f i a r © m o a n fJYA F F A / m g / h r ± SE . n = 5 ) 
GROUPS * 
I NLP-C 
II NLP-T 
III HLP-C 
IV HLP-T 
I vs II 
III vs IV 
I vs III 
HEPATIC LIPASE 
0.19 ± 0.01 
0.26 ± 0.01 
0.78 ± 0.17 
2.00 ± 0.30 
P <0.01 
C+3e. 8) 
p < 0 . 0 1 
c + 1 S 6 . A:> 
P < 0 . 0 l 
(+310.5) 
MYOCARDIAL LIPASE 
0.67 ± 0.003 
0.43 ± 0.002 
0.84 ± 0.08 
0.48 ± 0.07 
P <0.001 
C-35.83 
p <0.01 
C-45.23 
P >0.05 
(-25.3) 
T¥ V a L u e a i n p a r a n l h i « B e s s h o v p o r c o n l 
i n d l c a t o d . 
c h a n g e i n g r o u p s a o 
loe 
Tab Ie 22 
LIffect of HMG on the Activity of Post-heparin Plasma Lipase?; 
(Values aro moan /JM FFA/mL/hr ± SE , n = <l ) 
GROUPS * 
I NLP-C 
II NLP-T 
III JiLP-C 
IV HLP-T 
I vs II 
III vs IV 
I vs III 
HEPATIC LIPASE 
33.7 ± 1.7 
43.4 ± 7.6 
33.8 ± 0.9 
38.2 ± 1.2 
NS 
P <0.05 
C +1 3. 03 
LIPOPROTEIN LIPASE 
29.6 ± 2.3 
73.2 ± 4.6 
21.2 ± 1.6 
42.4 ± 8.7 
p <0.001 
C+14.7. 3D 
P <0.05 
C +99.OD 
P >0.05 
(-28.4) 
W- V a l u o s in p a r a n l h e o e o s h o w p o r c « n t 
I nd i. c a t ed . 
ttS = Nol « i. 9 n t f i, c a n I . 
c h a n g e in g r o u p s ao 
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of rats. The data in Table 22 show that after 
intraperitoneal administration of HMG to rats, activity of 
lipoprotein lipase was significantly increased to the 
extent of 147.3% and 99.0% in normolipidemic and 
hyperlipidemic* groups respectively. In case of hepatic 
lipase a significant increase of 13.0% was seen in 
hyperlipidemic rats whereas increase in normolipidemic rats 
(28.8%) was not significant. 
lr\ Vtxjo Effect of HMG on Platelet Aggregation : The results 
of platelet aggregation studies are reported in TciblG 23. 
HMG was able to significantly reduce the amplitude of 
ADP-induced aggregation in both normolipidemic and hyper-
lipidemic rats to the extent of 21.0% and 35.0%, 
respectively. In both the groups aggregation velocity as 
well as time required for maximum aggregation decreased 
nonsignifIcantly on HMG treatment except that only in 
hyperlipidemic animals the decrease in time required for 
maximum aggregation was significant (p <0.05). In diet 
induced hyperlipidemia, although a significant increase in 
amplitude of aggregation was not observed but the speed of 
aggregation was significantly higher (65.3%, p <O.OS) as 
compared to normolipidemic control group. 
ioe 
Tab Ie 23 
In. Vt-oo E f f e c t of HMG on B l o o d P l a t e l e t A g g r e g a t i o n 
< V a l u e B a r o m o a n ± S C , n = 5> 
GROUPS <* 
I 
II 
III 
IV 
I 
III 
I 
NLP-C 
NLP-T 
HLP-C 
HLP-T 
vs II 
vs IV 
vs III 
AMPLITUDE OF 
AGGREGATION 
(M C H A N G E IN OD> 
52.0 ± 2.1 
41.0 ± 2.3 
57.0 ± 3.7 
37.0 ± 3.8 
P <0.01 
C-21.1D 
p <0.01 
C-35. 03 
NS 
(+09.6) 
SPEED OF 
AGGREGATION 
< C M / M I N > 
25.4 ± 5.0 
20.8 ± 2.7 
42.0 ± 4.6 
34.3 ± 3.5 
NS 
c - i a . i D 
NS 
C-18. 31) 
P <0.05 
(+65.3) 
TIME OF 
AGGREGATION 
< S R C ) 
14.6 ± 2.4 
13.0 ± 1.2 
8.2 ± 0.5 
6.7 ± 0.4 
NS 
C-ll.OD 
P <0.05 
c - 1 0 . 3:> 
p <0.05 
(-43.8) 
>K A D P < 2 0 /LJM > vao u s o d as a g g r e g a l i n g a g o n l . 
\H V a L u o o in p a r a n l h o a o a o K o v p a r c o n l c h a n g o 
indi,oal«<l. 
N S = Not s i g n i f i c a n t . 
in g r o u p a ae 
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In Vitro Effect of HMG on Platelet Aggregation : When 
varying concentrations of HMG were tested for their effect 
on platelet aggregation, it was observed that HMG inhibited 
platelet aggregation in vitro and the extent of inhibition 
increased with increase in the amount of HMG added to PRP, 
as shown in TablG 24. At a concentration of 8 mg/mlj HMG 
completely inhibited the aggregation of platelets. 
no 
Ta.t>lG ad 
In Vitro Effect of HMG on Blood Platelet Aggregation * 
AMOUNT OF 
HMG 
( MO/ML. > 
0.0 
1.0 
2.0 
3.0 
4.0 
5.0 
AMPLITUDE OF 
AGGREGATION 
(M CHANOE IN OD> 
79.0 
52.3 
46.9 
30.15 
24.8 
22.11 
SPEED OF 
AGGREGATION 
< CM/MIN) 
21. 8 
8.7 
20. 6 
6.8 
8.0 
6.9 
TIME OF 
AGGREGATION 
( S E C ) 
32.4 
54.0 
20.4 
39.6 
27.6 
28.8 
4^  AUP ( 20 /JM > vas usod as ag g r ego. I I ng aganl 
m. 
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Atherosclerotic cardiovascular disease is responsible for 
50% of the death in the western world (Robert. 1988). In 
underdeveloped countries industrialization is also rapidly 
changing the lifestyle of individuals with the result that 
death due to coronary heart disease (CHD) is becoming more 
prevalent in such countries. It is very well known that 
cholesterol, accumulating in the wall of arteries, form 
bulky plaques that inhibit the flow of blood until a clot 
eventually forms, obstructing an artery and causing a heart 
attack or stroke. The association of hyperlipidemia with the 
development of atherosclerotic lesions has prompted 
widespread search for compounds which safely and effectively 
control the concentration of cholesterol and triglycerides 
in blood and hopefully in tissues with least or no toxic 
effects. 
Recently Gressman et al (1988) have reviewed the clinical 
trials and testing of the safety and efficacy of a new class 
of lipid lowering drugs which are competitive inhibitors of 
HMG-CoA reductase. One of these inhibitors, lovastatin 
formerly called roevinolln has been approved as a 
hypocholesterolemic drug by the U.S. Food and Drug Administ-
ration (FDA). Considering the same rationale and the fact 
that HMG is a competitive inhibitor of HMG-CoA reductase 
both tn. x>tx>o and tn. x)ttro (Fimognari and Rodwell. 1965; Bes. 
and LuEifiJl, 1972; MQQr.lani and LuEifin, 1977), back in 1967, 
i t. 
the work from this laboratory for the first time indicated 
that HMG has hypocholesterolemic activity (Eag. and Slddlqi, 
1967). Although work from different laboratories has 
unequivocally established the hypolipidemic effect of HMG 
(Caataner and Paton, 1978) there is a need to reinvestigate 
the mode of hypolipidemic action of HMG in light of the work 
on lovastatin and other HMG-CoA reductase inliibitors 
(Creaainan t^- CLI. 1988). 
The data given in rabt* 1 show significant decrease of 
total lipids in plasma of normolipideraic (18.6%) as well as 
hyperlipidemic (20%) rats on HMG treatment. This decrease 
was also reflected in total cholesterol, phospholipids and 
triglycerides. The compound was also significantly effective 
in lowering plasma total cholestex'ol, phospholipids and 
triglycerides of diabetic rats. It is evident from this 
table that fat-rich cholesterol diet as well as alloxan 
treatment caused significant elevation of all lipid para-
meters in plasma. It appears that HMG has a more pronounced 
hypotriglyceridemic effect in hyperlipidemic rats but a more 
pronounced hypocholesterolemic effect in diabetic rats. Tlie 
results are in agreement with the findings of Francesconi et 
aL (1987) in normal as well as diabetic rats but differed 
in magnitude which could be due to sex difference in the 
animals. We used male rats whereas they used female rats. 
In diabetic rats the difference in magnitude of reduction 
il3 
could also be atbributed to the difference in experimental 
manipulations of producing diabetes. They used streptozo-
tocin whereas we used alloxan. Even though we did not 
measure the concentration of plasma total lipids of diabetic 
rats, the reduction in lipid parameters confirms the hypoli-
pidemic action of HMG in diabetic rats also. 
Diabetic condition is known to be associated with hypertri-
Slyceridomia (EiiluL and Kraemer, 1988). Since HMG treobmenL 
significantly lowers triglyceride concentration in plasma of 
diabetic rats, it is safe to conclude that HMG appears to 
have a general hypolipidemic mode of action. The 
hypolipidemic action of a compound may involve its 
interference with lipoprotein synthesis or release or 
impaired lipid absorption. Since the defective lipoprotein 
metabolism or lipid transport could be a possible cause of 
hyperlipidemia or several kinds of hyperlipoproteinemias,the 
most logical mechanism of action of a hypolipidemic compound 
could be its interference with lipoprotein metabolism. 
It is now well established that several modalities of 
hypolipidemic therapy, including treatment with bile acid 
binding resins, fibric acid derivatives and weight 
reductions, produce significant alterations not only in 
the concentrations but also in the composition, structure 
and metabolism of lipoproteins (Goldberg <et ct{.,1987). It was 
interesting to note that in our experiments, HMG treatment 
11^ 
produced significant alterations in the plasma levels of 
lipoproteins and the concentrations of lipid components of 
almost all classes of lipoproteins. In all the experimental 
groups of rats, HMG treatment resulted in a fall of plasma 
levels of VLDL plus LDL accompanied by an increase of HDL in 
plasma (Tc3.t>l& 2 and TcxblG 3). VLDL and LDL are considered as 
atherogenic lipoproteins whereas high levels of HDL are 
protective against the development of atherosclerosis 
(Eiasaberg, 1984). 
Although total lipid content of VLDL in all the groups and 
of LDL in hyperlipidemic group was significantly lowered on 
HMG treatment but analysis of individual lipid components 
provided a better information about the effect of HMG on the 
lipoprotein lipids. Among HDL and its subfractions (HDL2 and 
HDLa), total lipid content of HDL3 was significantly 
decreased only in normolipidemic rats (Tc±>le 4). A 
significant change in the protein content of all plasma 
lipoproteins was not found {TciblG 5) except that VLDL+LDL 
protein was decreased in hyperlipidemic (16.9%) and VLDL 
protein was lowered in diabetic animals (22.2%). However, 
HDL protein was increased in normolipidemic rats 
significantly (22%). In other groups also it showed a 
tendency to increase. 
Further insight into the mechanism of plasma lipoprotein 
changes is provided by the analysis of lipoprotein lipids 
Ii5 
and the key enzymes of lipoprotein metabolism. The changes 
caused by HMG in lipid parameters of a combined fraction of 
VLDL plus LDL {Tahle 6) are such that these lipoproteins 
show a tendency to decrease as is clearly evident from the 
decrease in the concentration of all lipid components in 
this lipoprotein fraction (Fig. 6). 
A significant lowering effect of HMG on the concentration of 
triglycerides and cholesterol associated with VLDL+LDL,which 
are the determining factors of these lipoproteins, suggest 
that HMG exerts a stimulatory effect on the catabolism of 
these lipoproteins. In the earlier reports, on the basis of 
observation that HMG treatment in rats caused a decrease in 
blood lipids without any increase in the liver lipids, 
Yousufzai and Siddigl. (1976b), ruled out the possibility of 
HMG inhibiting the release of VLDL and LDL from the liver. 
The observations were more clearly evident when effect of 
HMG on lipid parameters was seen in separate fractions of 
VLDL and LDL. 
Table 8 and Table ii show the effect of HMG on VLDL and LDL 
lipids respectively. Plasma triglyceride lowering activity 
of HMG is found to be associated with a concomitant decrease 
of triglycerides of both VLDL and LDL. Plasma cholesterol 
lowering activity also seems to be contributed by lowering 
of both LDL-cholesterol and VLDL-cholesterol. The 
observation that HMG lowers atherogenic lipoproteins in 
i i 6 
plasma {TaJble 2 and Tc±>L& 3) can be explained from these 
changes caused by HMG in the concentrations of VLDL- and 
LDL-lipids. Probucol also acts by lowering LDL-cholesterol 
but it causes more marked regression of xanthomas than would 
be expected from the extent of lowering of LDL-cholesterol. 
Probucol seems to act by increasing LDL removal by a 
receptor independent mechanism. Since all the lipid compo-
nents of VLDL are decreased iTable- 8, Fig. 7) it is likely 
that HMG either brings about the degradation of these lipo-
proteins resulting into lowering of their plasma levels or 
inhibits the synthesis of VLDL. 
On the basis of the observation that HMG markedly enhances 
the activity of post-heparin plasma lipoprotein lipase 
{Tabl« 22), it is most likely that the catabolism of VLDL is 
enhanced. Upon hydrolysis surface lipids are removed from 
VLDL and the remnants thus produced are taken up by receptor 
mediated process by the liver. Thus, enhanced hydrolysis of 
VLDL caused by HMG might result into less availability of 
LDL precursor i.e. VLDL thereby decreasing the concentra-
tions of LDL lipids also {Ta.hi& ii). Contrary to this, Ariia 
Of- CLl (1986) suggested that since HMG reduces hepatic 
cholesterol synthesis, this miglit inhibit the secretion of 
LDL precursor (VLDL) from the liver. Their data in FH and 
polygenic hypercholesterolemia support this hypothesis. 
The effect of HMG seems to depend on the metabolic condi-
ii7 
tions of animals. In induced hyperlipidemia, concentration 
of cholesterol in VLDL was maximally decreased (Table 8, 
Fig. 7).In contrast J phospholipids,triglycerides as well as 
total lipids of VLDL were significantly decreased in rats 
fed on basal diet, indicating an overall reduction in the 
total mass of this lipoprotein. In diabetic rats also, the 
concentrations of all the lipid components of plasma VLDL 
were lowered (Tabie S. Fig. 7) , Similarly the diffei-ences in 
the response to HMG was observed for LDL-lipids as shown in 
Fig. 8. Normolipidemic group showed an increase of LDL-phos-
pholipids associated with the decrease of other lipids. The 
hyperlipideroic rats showed a lowering of total mass of this 
lipoprotein but diabetic rats did not show any change in 
LDL-trlglycerides although both cholesterol and phospho-
lipids were decreased (Table ff). Carlson, et al (1977) have 
reported that clofibrate caused an elevation of 
LDL-cholesterol in hypertriglyceridemic patients with 
LDL-cholesterol below 140 mg/dL but tlie reverse is true when 
LDL-cholesterol levels are over 140 rag/dL. As far as the 
percent composition of lipoproteins is concerned, the compo-
sition of LDL (7-a6l«> 12) was altered more significantly than 
the composition of VLDL (Table lO) in normolipidemic and 
hyperlipidemic groups.However, phospholipid and triglyceride 
composition of VLDL was significantly changed in diabetic 
rats, without any significant change in LDL composition. 
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These observations do not give any indication about signifi-
cant effect of HMG on the percent lipid composition of 
circulating lipoprotein particles. Enhanced hydrolysis of 
VLDL upon HMQ treatment might have resulted in a substantial 
rise of LDL levels. Since we did not find any increase in 
LDL- cholesterol, which is an indicator of plasma LDL 
levels, it is likely that either LDL particles are 
increasingly removed from the circulation or there is a 
rapid uptake of VLDL remnants by the liver in response to 
HMG administration. This is in agreement with the rationale 
of using HMG-CoA reductase inhibitors to effectively lower 
plasma LDL-cholesterol levels. The inhibition of intra-
cellular cholesterol biosynthesis would result into an 
increased expression of receptors on the cells surfaces, 
responsible for the uptake of both VLDL remnants and LDL 
(Fig.3). 
Diabetic condition is regarded as the model for hypertrigly-
cez'idemia as is also evident from elevated levels of plasma 
triglycerides in diabetic rats in comparison to normal rats 
{Table' i). Lipoproteins and lipids ar-e frequently altered in 
diabetes. These lipoprotein alterations are of interest 
because of their possible role in the origin of accelerated 
atherosclerosis found in diabetes. It is well known that in 
diabetes there is an increased formation of acetyl CoA, a 
precursor for both cholesterol and acetoacetate syntliesis 
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(Brownlee and Ceraml, 1981). Macrophages from insulin 
doficiont mice have increased activity of HMG-CoA reductase 
and subsequently an increased rate of cellular cholesterol 
synthesis (Kraorner, 1986). More recently, a decreased 
secretion of lipoprotein lipase has been reported by insulin 
deficient macrophages (Efiiir. and Kraemer, 1988). The change.^ 
in cholesterol metabolism appear to be secondary to a 
decrease in the number of receptors responsible for the 
uptake of VLDL fKraemer, 1986). These receptors probably 
represent LDL receptors in that the uptake of both LDL and 
VLDL by macrophages is mediated by the LDL receptors (Kj2i2 
^t a.1, 1986; Ellsworth et CLI , 1987). In the presence of 
decreased LDL receptors, the low level of lipoprotein lipase 
secreted by macrophages would be expected to further hinder 
the uptake of triglyceride rich lipoproteins (Belir and 
Kraemer, 1988). As opposed to lipoprotein lipase secretion, 
in x>i-oo insulin treatment normalizes the activity of HMG-CoA 
reductase, cellular cholesterol synthesis and LDL receptor 
expression. 
High levels of triglycerides associated with high levels of 
atherogenic lipoproteins in plasma has consistently been 
reported in diabetes. Our results also confirm these changes 
in diabetic rats in comparison to normolipidemic rats (Table 
i and Table 2).Since VLDL are the main triglyceride carrying 
lipoproteins, effectiveness of HMG under diabetic condition 
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is of significance. HMG induced compositional changes of 
lipoproteins in normolipidemic rats appear to differ from 
those produced in rats of diabetic group. 
A high cholesterol : triglyceride ratio in VLDL fraction has 
been reported in animals receiving diet rich in butter 
and cholesterol (OH vier t^t a.1, 1988). Our results also show 
an increased cholesterol : triglycerides ratio of VLDL in 
hyperlipidemic rats (fed with fat-rich cholesterol diet as 
described in methods) (Table 9 ) . This ratio was not changed 
significantly upon HMG treatment in normolipidemic group. In 
contrast, hyperlipidemic and diabetic rats treated with HMG 
showed a low mean cholesterol : triglycerides ratio of VLDL 
indicating the selective depletion of cholesterol in this 
lipoprotein fraction in comparison to triglycerides. It 
may mean that HMG did not produce proportionate decrease of 
cholesterol and triglycerides in VLDL. The effectiveness of 
HMG on the composition of lipoproteins resembles to that of 
fenofibrate (Goldberg et al. 1987) and acipimox (Taakinen 
and Nikkl la. 1988). In both the cases the decrease of VLDL 
lipids was associated with a rise of HDL-cholesterol. In our 
observations the magnitude of increase in HDL-cholesterol 
was more pronounced in hyperlipidemic and diabetic group-o 
(Fig. 9 ) . Thus VLDL and LDL lost cholesterol in response to 
HMG administration and HDL fraction became enriched in 
cholesterol and relatively more depleted in triglycerides 
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(Tattle 13). The rise of HDL-cholesterol seeras to be mainly 
due -to a rise of lIDLj-cholesterol (Table 14, Fig. lO) in 
both hyperlipidemic and diabetic groups. Since cholesterol 
and phoflpholipida are the major components of HDL, their 
concentrations are indicative of the plasma levels of this 
lipoprotein. Although the concentration of phospholipids 
in HDL did not change significantly but it also exhibited an 
increasing trend indicating an increase of total HDL mass. 
Again this effect of HMG was more pronounced in HDL2 sub-
fraction (Table 14) which was highly significant in diabetic 
rats (p <0.001, 317.0%). The increase of both cholesterol 
and phospholipid concentration in HDL^ suggests a rise in 
HDL2 mass. In HDLa subfraction phospholipid concentration 
was decreased {Table 15, Fig. 11). These observations can be 
correlated with those reported in Table 2 and Table 3 and 
it may be suggested that the elevated plasma HDL levels, as 
indicated by turbidimetric analysis as well as agarose gel 
electrophoresis (Fig. 5),are mainly contributed by HDL2 
subfraction. Although we have not measured the level of HDL 
subfractions in plasma, the analysis of subfraction lipids 
supports the idea that action of HMG involves mainly HDL2 
subfraction. This is again in agreement with the increased 
ratio of HDLz-cholesterol : HDLg-cholesterol.of treated rats 
(Table 16). The process of enhanced hydrolysis of VLDL, in 
response to HMG treatment and accompanied transfer of 
taa 
aurfncft conipor»oi>l-n of VIiDL to i\n;^ ocnt HDL (Xfinooi nl,<><i w n>h 
the uptake of tissue cholesterol by HDL3 to form IIDL2 (Fig. 
2),is supported by the observation of increased lipoprotein 
lipase activity in HMG treated rats {Tahle 22). The 
possibility of inhibition of VLDL production and release by 
liver can again be ruled out since HMG does not inhibit the 
lipolysis as a result it may not reduce the flux of FFA to 
the liver and consequently VLDL production. In this regard 
HMG differs in its action of lowering VLDL lipids from 
acipimox fTaskinr^n and Mjkkila, 1988) which lowers VLDL 
production by inhibiting FFA flux to the liver. 
It is, therefore, logical to conclude that HMG resembles a 
new class of lipid lowering agents namely competitive 
inhibitors ofHMG-CoA reductase. They exert their action by 
stimulating a compensatory increase in the expression of LDL 
receptors on cell surface (hepatocytes) of liver as shown in 
Fig. 3, which reclaim circulatory cholesterol (LDL-
cholesterol) to meet cellular metabolic needs (Gordon and 
Rifkind, 1987). This process augments the removal of VLDL 
remnants (produced as a result of lipoprotein lipase 
activity on VLDL) and LDL from the circulation. In addition, 
production of LDL is reduced, since these cholesterol-rich 
lipoproteins are derived from VLDL remnants (Cressman et a.1. 
1988), Hence the level of intracellular cholesterol 
synthesis is an important determinant of blood LDL-
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cholesterol levels. In our investigation on the effect of 
HMG on LDL lipido {TaJblo //) it is interesting that the 
percent reduction in total plasma cholesterol and 
LDL-cholesterol levels is quite similar and significant in 
normal as well as hyperlipidemic and diabetic rats in 
contrast to HDL-cholesterol and HDLz-cholesterol which are 
significantly increased in hyperlipidemic and diabetic rats. 
Hence, it may be proposed that the augmented removal of VLDL 
remnants and LDL from the circulation, as a result of 
inhibition of intracellular cholesterol synthesis (Fig. 3) 
in presence of HMG, might in turn enhance the activity of 
lipoprotein lipase to maintain a critical intracellular 
cholesterol level. This proposed mechanism gets strong 
support from our observation that HMG treatment resulted in 
significant enhancement of the activity of lipoprotein 
lipase in post-heparin plasma of both normolipidemic and 
hyperlipidemic rats to the extent of 147% (p <0. ooi) and 
100% (p <0.05), respectively {Table 22:>, These effects are 
similar to lovastatin and bile acid sequestrants. Both have 
been postulated to increase the activity of LDL receptors 
fPaoletti and EQIJL, 1987) and this common mechanism has been 
put forth to explain the reduction in levels of 
LDL-cholesterol in hypercholesterolemic patients during drug 
therapy. Clofibrate and bezafibrate also exert their effects 
on lipoproteins by increasing the catabolism of triglyceride 
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rich lipoproteins (Goldberg et al, 1979; Vessby et al. 
19S2). Similar to the action of fibrates (Slrtorl and 
IVrnnnefto.hini. 1988) , the increased lipoprotein lipase 
activity in HMG treated rats may also result from the 
elevation of the apoC-II content of VLDL which is the 
activator of lipoprotein lipase. An increase in apoG 
proteins of VLDL + LDL fraction is shown in Fig. 12. The 
rise in apoC content of VLDL in HMG treated rats seems to be 
due to the transfer of apoC-II and apoC-III from HDL. At the 
same time irKireased activity of hepatic lipase in 
post-heparin plasma seems to be a secondary effect produced 
as a result of increased lipoprotein lipase activity {Tcthle 
22) . Since surface components of triglyceride rich lipo-
proteins, upon hydrolysis, are transferred to HDLg resulting 
into the production of less denser HDLz particles, the 
enhanced activity of lipoprotein lipase reflects,indirectly, 
the enhanced HDL2 levels. 
It has been demonstrated that lipoprotein lipase regulates 
firstly the catabolisra of triglyceride rich particles and 
secondly, also the formation of HDL (HDL2) f Patsch et ctL, 
1978; Nikkila. 1984). Thus lipoprotein lipase activity is 
not only a regulator of triglyceride concentration in plasma 
but io also a determinant of HDL levels. In vivo lipoprotein 
lipase and hepatic lipase activity are regulated indepen-; 
dently but act concomitantly (Nikkila, 1984) and ,therefore, 
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the rat.io of two lipase activities would be crucial. 
Triglyceride rich HDL2 particles serve as a good substrate 
foi* hepatic lipase and are converted to HDL3 whereas trigly-
ride poor HDL^ is not degraded by hepatic lipase (Eaiiiicil e^t 
ctl, 1984). Hepatic lipase breaks down HDL2 particles through 
its phospholipase activity and is thus the key enzyme in the 
removal of HDL2 particles. It may be pointed out that 
average value of lipoprotein lipase activity was lowez- in 
hyperlipidemic than in the norraolipidemic rats and HMG 
treatment resulted in the enhancement of the activity of 
both enzymes in post-heparin plasma {Tc±>le 22) . A similar 
effect of HMG was observed on hepatic lipase measured in 
liver homogenates {Table 21). Myocardial lipase, which was 
measured in heart horaogenate, differs from hepatic lipase in 
its metabolic function. This is localized on the capillary 
wall of the endothelial cells of rat heart (Twu et CLL , 1975) 
and has been reported to hydrolyze diglyceride monolayers as 
well as triglyceride monolayers (Qhung and SiiarLa. 1977) and 
monoglycerlde in miceller or albumin bound substrates (THJA 
<&t al, 1976). The physiological role of this lipase lies in 
the assimilation of triglyceride fatty acids into the 
tissue. 
Our results indicate that the triglyceride concentration of 
HDL is maximally decreased (Table 13). This effect of HMG on', 
HDL triglycerides was also cleai-ly reflected in its 
i2G 
subfrac-bions (Ta&le 14 and TablG i5). Patach Gt al. (1984) 
showed that the triglyceride content of HDLj was a crucial 
factor in hepatic lipase mediated conversion of HDL2 to 
HDLg. Increased triglyceride concentration in HDL has been 
reported in postprandial liperaia in norraotriglyceridemics 
(putsch et al, 1984) and in hypertriglyceridemics with 
elevated triglyceride levels (Eisenberg et al, 1984). Since 
triglyceride rich IIDL2 particles serve in xjitro as a good 
substrate for hepatic lipase whereas triglyceride poor HDL2 
is not degraded by hepatic lipase (Patsch et ctl, 1984), it 
is likely that HMG might enhance this process and hence, as 
a result, HMG treated rats showed presence of triglyceride 
poor HDL2 in plasma (Tafcle 14). Increased activity of 
hepatic lipase in treated rats {TabL^ 21 and Table 22) seems 
to be responsible for the clearing of triglyceride rich HDL2 
in these rats as compared to control rats showing 
significantly higher concentrations of triglycerides in 
their HDL2 subfraction. Increased cholesterol and 
phospholipid concentrations of HDL and HDL2 in HMG treated 
rats suggested increase in plasma concentration of HDL in 
comparison to saline treated rats. Same conclusion can be 
drawn from the results obtained after SDS-PAGE of apolipo-
proteins of HDL subfractions. Here again the apolipoproteins 
of HDLj and HDL3 provided more clear information than total 
HDL, regarding the increase of HDL. The increase in total 
isr? 
mass of HDL can be explained by a visible increase of apoE 
and apoA-I of HDL^ in both hyperlipidemic and diabetic rats 
(Fig. 14.) , This was also associated with an increase of 
apoA-IV and apoA-II in case of diabetic rats treated with 
HMG. However, the increase in HDL^ was not reflected in 
apolipoprotelns of normal rats. These results are consistent 
with the proposition that HDL rise is mainly reflected in 
its HDLz aubfraction. Although apoE of HDLg was also 
increased in diabetic treated rats but apoA-I was 
considerably decreased (Fig. 15) which does not reflect a 
net increase in HDL3. Although HMG and lovastatin belong to 
the class of HMG-CoA reductase inhibitors, their mode of 
hypolipidemic action appears to be different, Lovastatin 
action on lipoprotein profile does not seem to be mediated 
by lipoprotein lipase or hepatic lipase CHelve and Tikkanen. 
1988) both of which are known to regulate HDL levels. 
Therefore, lovastatin-mediated lowering of LDL-cholesterol 
has been explained in terms of Increase in the number of 
LDL receptors only (Goldstein and Brown. 1984b; Bilheimer &t 
a.L, 1983). HMG significantly increases the activity of both 
lipases exhibiting an effect similar to that of bezaflbrate 
(Gavish et aL. 1986). Hence, it is tempting to speculate 
that mode of action of HMG is not only mediated through 
increase in LDL receptors, as suggested by Goldstein and/' 
Brown (1982) for the inhibitors of cholesterol biosynthesis. 
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but. also increase in the activity of these lipases. Like 
bezafibrate the decrease of plasma triglycerides is most 
probably attributed to the increased lipoprotein lipase 
activity. It is noteworthy that an elevation of HDL-
cholesterol was observed inspite of an increase in the 
activity of hepatic lipase. Several investigators suggested 
that higher hepatic lipase activity are associated with 
decreased HDL-choleaterol concentrations (Kuusi et a.1, 1900; 
fiao. et a.1, 1982). It may be inferred that this mechanism 
either does not operate or is masked by activation of 
pathways that caused increased HDL-cholesterol concentration 
in plasma as discussed in previous pages. 
The protective action of HDL against the development of CHD 
is believed to arise through the process of reverse 
cholesterol transport by which surplus cholesterol from the 
extrahepatic tissues, including artery walls and tendon 
xanthomas, is transported in association with HDL to the 
liver for excretion in the form of bile salts (Reichl and 
tmieil. 1986; Elsenberg. 1984). Although a low level of 
HDL-cholesterol is recognized as a major cardiovascular 
disease risk factor, there is evidence that it is the HDLz 
subfraction which is the principal determinant of risk. HDLg 
does not appear to be a risk factor (Eaae ^f- ai, 1988). 
While the majority of studies have not implicated HDLg as a 
risk factor, its plasma levels have been shown to be 
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sensitive to diet and alcohol intake (Williams. <^t al, 1985; 
piQhl &t al, 1988). Low HDL-cholesterol levels are also a 
particular feature of hypertriglyceridemia. There is a well 
established inverse correlation between plasma triglyceride 
concentration and HDL-cholesterol, primarily the HDLz 
subfraction (DacJiGJJbaum <?t ai, 1984; liong. ©t al, 1988). This 
strong negative relationship of HDLz-cholesterol with plasma 
triglyceride found in many studies is compatible with the 
hypothesis that HDL2 is formed, at least in part, from HDL3 
by the lipolysis of triglyceride rich lipoproteins, mediated 
by lipoprotein lipase (Taskinen and Mlkklla. 1981). 
The ratio of plasma cholesterol to HDL-cholesterol (Castelli 
1984) and the ratio of VLDL + LDL-cholesterol to HDL-
cholesterol (Mil] er &t al. 1982) has been reported to be 
indicators of CHD risk. Several reports have indicated that 
an elevated ratio of plasma cholesterol to HDL-cholesterol 
might contribute to the development of coronary athero-
matosis (fctaiXanlJLii and Moberg, 1982; Jackson and Lfi.e., 1984). 
From our data (Table 20) it can be seen that rats from 
different groups showed significantly different coronary 
risk indices. As expected, this was highest in 
hyperlipidemic rats and decreased after HMG treatment, 
significantly, in all the groups. The lowering of these 
ratios can be explained on the basis of the HDL-cholesterol 
increasing effect of HMG. Accordingly, the decrease was 
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maximum in diabetic rats. In a study involving subjects 
witVi different coronary risks indices, Griffin et al (1968) 
have recently reported a higher concentration of HDL-
cholesterol in the lower risk group. It can be suggested 
that, like cholestyramine (Jones et al,1984) and bezafibrate 
fflavish et al,1986), HMG administration is also effective in 
reducing these indicators of atherogenic risk. According to 
the current concepts of atherogenicity of plasma lipo-
proteins, these effects are desirable and should result in a 
decreased tendency to develop atherosclerotic disease. 
The ability of HMG to counteract triton-induced hyper-
lipidemia in rats suggested that HMG might be exerting its 
hypolipidemic effect through inhibition of lipoprotein 
synthesis (Yousufzai and Siddioi. 1976c). Since HMG was 
unable to overcome orotic acid-induced fatty liver changes 
in rats fYousufzai and Siddial. 1977c). the possibility of 
HMG inhibiting the synthesis of VLDL and LDL rather than 
release was considered more plausible as the decrease in 
serum lipids was not accompanied by a rise of liver lipids 
(Yousufzai and Siddigi, 1977a). The hypocholesterolemic and 
hypotriglyceridemic activity of HMG has also been 
demonstrated in streptozotocin-induced diabetic rats 
(FranceRconI et al. 1987). As shown in TabLe 1 HMG is 
equally effective in alloxan-induced diabetic rats. In light 
of these observations and the current knowledge of rolo of 
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cAMP in regulating the lipolysis. it is tempting to suggest 
that like nicotinic acid,activity of HMG is mediated through 
its action on adenylate cyclase. It would, therefore, be 
expected that level of this enzyme would be increased in 
triton-induced hyperlipidemia. It has been recently shown 
that hepatic adenylate cyclase as well as guanylate cyclase 
increased by 234.0% and 96.0%, respectively, in triton-
induced hyperlipidemia as compared to control rats. The 
administration of HMG (t.p.) for two weeks at the dose level 
of 25 mg/Kg body weight decreased the activity of adenylate 
cyclase and guanylate cyclase to the extent of 40.0% and 
34.0%, respectively [Personal communication, Dr. A.N.K. 
Yusufi, Department of Biochemistry,Faculty of Life Sciences, 
Aligarh Muslim University, Aligarh]. The inhibitory effect 
of insulin, nicotinic acid and prostaglandin E^  on adipose 
tissue lipolysis has been explained in terms of inhibition 
of the synthesis of cAMP possibly at the level of adenylate 
cyclase site or by stimulating phosphodiesterase. Since HMG 
decreased the activity of adenylate cyclase, it is quite 
likely that the action of HMG is mediated through the 
inhibition of adenylate cyclase. 
iTrancesqpni et aL, (1987) have observed that HMG 
administration to streptozotocin-induced diabetic rats 
produced only a slight, increase of HDL-cholesterol (4.0%),' 
the level of which was significantly lower (p <0.01) in the 
i3a 
plasma of these animals than in the plasma of controls. The 
trend, towards an increase of HDL-cholesterol levels 
parallel to the tendency towards a decrease of plasma total 
cholesterol, was considered to indicate an effect of HMG on 
lipoproteins related to its hypolipidemic and hypoketonemic 
action. These observations led the authors to believe that 
HMG administration partially counteracts some of the effects 
produced by diabetogenic agent streptozotocin. In the 
present study we have shown the effect of HMG administration 
in normolipidemic, hyperlipidemic and alloxan-induced 
diabetic male rats. HMG administration to our diabetic 
animals produced a marked increase in plasma HDL-cholesterol 
48.0% (P <0.05) than in the plasma of control animals (Table 
i3) . As shown in TcLhle i the magnitude of increase in plasma 
HDL-cholesterol was approximately of the same order as that 
of decrease in total cholesterol (32.0%, p <0.OS).Therefore. 
we confirm that HMG administration has the capability to 
counteract the effects produced by diabetogenic agent 
alloxan. Our observations also confirm the findings of 
Francesconl &t al, (1987) that the effect of HMG was more 
pronounced in diabetic than in normal rats. This is due to 
higher uptake of HMG found in the diabetic group in 
comparison with the controls (Francesconl et CLI . 1987). 
Considering that there is an increased HMG concentration in 
urine (Deana <?t al. 1982) as well as in plasma f Lippe et a.1, 
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1987) of both diabetic patients and rats, the authors have 
speculated that increased uptake and excretion of HMG in 
diabetes may be due to an alteration of the membrane permea-
bility or to some other unknown factors. A model for the 
hypolipidemic action of HMG has been proposed in Fig. IG. 
Platelet activation has been shown to be associated with 
hyperlipidemia and atherosclerosis both in humans and exper-
imental animals (Aviram and Brpok. 1987). Considerable 
evidence suggest that high plasma LDL-cholesterol levels are 
also associated with increased platelet aggregation. Hence 
the atherogenic property , of LDL and VLDL as well as 
antiatherogenic property of HDL have been attributed to 
their effects on platelet function (Avjram and Briiaii, 1987). 
Plasma lipoproteins affect platelet activity by modulation 
of arachidonate pathway, cAMP formation and phosphoinositide 
metabolites (A^ LLriun, 1988). The overall metabolism of 
arachidonic acid was found to be increased in platelets from 
patients with type IIA hypercholesterolemia (Eynard ct a.1, 
1986) probably due to the modification of the lipid 
composition of platelet membranes. KamjdQ et at (1988) have 
reported a lower phosphocholine : cholesterol ratio in 
platelets from such patients. This ratio is' an important 
determinant of platelet membrane fluidity. The lipid 
composition of platelets affects not only membrane fluidity 
of platelets but also prostaglandin metabolism and thus 
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affects aggregation of platelets. In \>itro studies have also 
shown that cholesterol enriched platelets produced increased 
amount of thromboxane B2 as compared to cholesterol poor 
platelets. The increased formation of arachidonic acid 
metabolic products, not only via cyclooxygenase but also via 
lipooxygenase pathway, may thus contribute to hyper-
aggregability, associated with the hyperlipidemic state 
(Tremoli and NlCQsla, 1983). 
As also discussed earlier, it is now well established that 
compounds inhibiting platelet aggregation might retard 
atherogenesls. Witiak et al (1988) have recently reviewed 
the activity of various antilipidemic and antiaggregatory 
agents, some of which also lower serum LDL and VLDL 
concentrations. Hence the effectiveness of HMG {in vivo) in 
decreasing the platelet aggregation (Table 23) can well be 
attributed to its capacity to reduce LDL-cholesterol as well 
as plasma levels of atherogenic lipoproteins (LDL+VLDL). The 
ability of HMG to inhibit ADP-induced platelet aggregation 
both in vivo {Tablfs 23) and in vitro {TaJbl6 24) suggest that 
the compound may physiologically modulate platelet 
function. This modulation is also exhibited by the 
alterations in the speed of aggregation as well as time for 
maximal aggregation. Since platelets contribute to the 
formation of atherosclerotic lesions by enhancing foam cell 
formation (Taka^i et a.1, 1988), the inhibitory action of HMG 
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on pla"telet aggregation support, the usefulness of this 
compound as an antihyperlipidemic and antiaggregatory agent. 
It can be suggested that HMG treatment produces an 
alteration in the lipid composition of platelets as a result 
of the changes produced in plasma lipids and lipoproteins. 
Aviram and Brook (1982) have reported that increased 
platelet activity in patients with FH is dependent on the 
exposure of platelets to some plasma constituent(a). It 
appears, more than likely, that the cholesterol containing 
particles such as LDL, through interaction with the 
platelets, are important in this regard since platelets 
possess specific binding sites for LDL (Aviram and Brook. 
1981a,b) and serve as cholesterol storage organs (Block et 
al, 198a) after the uptake of lipoprotein cholesterol. The 
changes in the membrane cholesterol content of platelets, as 
a i'esult of alteration in plasma lipids produced by HMG 
treatment, are therefore expected to be responsible for tlie 
decreased aggregation. This may involve the alterations in 
the arachidonic acid metabolism. Theoretically, compounds 
inhibiting platelet aggregation could possibly do so by a 
variety of mechanisms (Philp. 1981). Increased platelet 
aggregation in type IIA hypercholesterol'emic patients have 
been attributed to increased metabolism of arachidonic acid 
(Evnarcj &t al. 1986). Hence, it is most likely that 
hyporesponsiveness of platelets, derived from HMG treated 
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rats, to aggregating agent may be consequent to the 
cholesterol (LDL-cholesterol) lowering effect of HMG in the 
plasma and the effect of HMG seems to be mediated via the 
arachidonic acid pathway, gynayd et a.1 (1986) have explained 
the changes of arachidonic acid metabolism by at least 2 
mechanisms: modifications of the cholesterol and 
phospholipid content of platelet membranes and or 
modifications in the platelet enzyme activities. The effect 
of HMG on platelet aggregation is of interest because of 
their relatioship to atherosclerosis. It will be desirable 
to perform platelet aggregation studies in diabetic rats 
also. 
From the foregoing discussion it appears that HMG may be a 
more beneficial therapeutic agent than other conventionally 
used compounds and drugs. However, more biochemical, 
pharmacological and clinical studies are needed in higher 
primates before it can qualify as a hypolipidemic drug for 
human consumption. A comparison of lipid lowering effect of 
HMG and other widely used compounds/drugs is summarized in 
Tabid 25 which supports the contention that HMG may be a 
potential drug of future in combatting hyperlipidemia. 
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TablG 25 
COMPARISON OF HMG AND OTHER HYPOLIPIDEMIC COMPOUNDS/'DRUGs'^ 
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Drugs designed to lower circulating atherogenic lipoproteins 
such as VLDL and LDL or to increase the putative anti-
atherogenic HDL, are used in the expectation that they will 
retard or even reverse the atherosclerotic process. The 
process of selection of new agents of this kind is usually 
based on assessment of their effect on circulating lipids 
and lipoproteins in laboratory animals. In the present work 
efforts have been made to show that HMG could be a promising 
hypolipidemic drug of future after a systematic clinical and 
pharmacological screening. 
To investigate the mechanism of lipid lowering action of 
HMG, the effects of i.p. administration of HMG were studied 
in norraolipidemic, hyperlipidemic and diabetic rats. Rats 
were made hyperlipidemic by feeding them fat-rich 
cholesterol diet. Diabetes was experimentally induced in 
rats by alloxan treatment (i.v.). These rats were treated 
(i.p.) with HMG (25.0 rag/kg body weight). Rats treated with 
saline served as corresponding controls in each of tlie 
experimental groups. Plasma lipids, lipoproteins, post-
heparin plasma lipases, tissue myocardial and hepatic 
lipases were analyzed in both HMG treated and control i-ats. 
Platelet aggregation studies were also carried out. 
1. Earlier observations were confirmed that HMG 
effectively lowers plasma lipids in both normolipidemic and 
hyperlipidemic rats. HMG was also found to effectively lower 
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plasma lipids of alloxan-induced diabetic rats. 
2. Plasma lipoproteins were measured turbidimetrically and 
by agarose gel electrophoresis. In all the experimental 
groups, HMQ was found to lower the levels of atherogenic 
lipoproteins (VLDL+LDL) and to raise the levels of HDL in 
plasma. 
3. Analysis of the lipid parameters (cholesterol, 
phospholipids, triglycerides) of Individual lipoproteins 
provided a better information about the mode of action of 
HMG involving its effect on lipoproteins. 
4. Concentration of all the lipid parameters were 
decreased in a combined fraction of VLDL plus LDL, signi-
ficantly, in each of the experimental group treated with HMG 
indicating an over all decrease of these lipoproteins. 
5. VLDL-cholesterol, VLDL-phospholipids and VLDL-
ti'iglycerides were also decreased significantly. HMG 
treatment also resulted in a decrease of VLDL-cholesterol : 
VLDL-triglyceride ratio in hyperlipidemic and diabetic rats 
indicating a selective depletion of cholesterol in this 
lipoprotein fraction. 
6. LDL lipids were measured indirectly based on the values 
of VLDL and VLDL+LDL lipids. LDL-cholesterol and LDL-
triglycerides were significantly reduced. LDL-phospholipid 
was either decreased or remained unchanged. / 
7. HMG treatment resulted in a significant increase of 
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HDL-cholesterol in hyperlipidemic and diabetic rats and a 
nonsignificant increase in normolipidemic rats. HDL-
triglycerides were decreased significantly in all the groups 
but no significant effect was observed on HDL-phospholipids. 
8. A more clear information regarding the effect of HMG on 
HDL was drawn from the analysis of HDL subfractions. The 
concentration of cholesterol and phospholipids increased in 
HDLz subfraction. The increase was more significant in 
diabetic group than in hyperlipidemic group but was non-
significant in normolipidemic group. Increase in HDL3-
cholesterol did not show statistical significance. However, 
HDLa-phospholipids decreased in diabetic group and 
HDLa-triglycerides in hyperlipidemic group significantly. 
The ratio of HDLz-cholesterol : HDLg-cholesterol was higher 
in all the groups treated with HMG. From these observations 
it is inferred that among HDL subfractions, HMG has a more 
pronounced effect on HDL^ than HDLB. 
9. HMG treatment also resulted in a, decrease of the 
indicators of atherogenic risk which are given in terms of 
the ratio of plasma cholesterol : HDL-cholesterol and the 
ratio of VLDL+LDL-cholesterol : HDL-cholesterol. The effect 
was more significant in hyperlipidemic and diabetic rats 
than normolipidemic rats. 
10. Besides affecting the lipid components of lipoprotein.^ 
HMG also affected the apolipoproteins of different 
i42 
lipoprotein fractions indicating that the mode of action of 
HMG involves its interference with the lipoprotein 
metabolism. 
11. Lipoprotein lipase and hepatic lipase are the key 
enzymes involved in the metabolism of lipoproteins. HMG 
treatment produced an increase in the activity of these 
lipases. The effect was more pronounced and significant for 
lipoprotein lipase than for hepatic lipase. 
12. Both in vix)o and in rjttro, HMG inhibited ADP-induced 
aggregation of blood platelets. The speed of aggregation as 
well as time for maximum aggregation also decreased in HMG 
treated rats. 
HMG belongs to the class of lipid lowering agents which ai-e 
competitive Inlxlbitors of HMG-^CoA reductase. The action of 
HMG appears to involve enhancement in lipoprotein lipase 
mediated hydrolysis of triglyceride rich lipoproteins. This 
process would be accompanied by an increased conversion of 
HDLa to HDL2,which is the preferred substrate for hepatic 
lipase. The increase in the activity of hepatic lipase upon 
HMG treatment supports this view. The enhanced activity of 
plasma lipoprotein lipase may explain the lowering of plasma 
atherogenic lipoproteins in response to HMG treatment. 
Increase of plasma HDL by HMG was due to an increase in its 
HDL2 subfraction. Since inhibition of intracellular 
cholesterol biosynthesis is known to enhance the expression 
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of receptors, responsible for the uptake of both VLDL 
remnants and LDL on cell surfaces, it is suggested that 
increased number of receptors in response to HMG treatment 
might have resulted into augmented removal of circulating 
VLDL remnants and LDL to fulfil cellular demand for 
cholesterol through receptor mediated endocytosis. Enhanced 
activity of lipoprotein lipase would then be responsible to 
maintain a critical Intracellular cholesterol level. A model 
for hypolipidemic action of HMG has been proposed (Fig- 16). 
The effect of HMG was dependent on the physiological 
conditins of the animals. A more pronounced effect of HMG in 
diabetic rats, observed in all the investigations, has been 
explained in terras of higher uptake of HMG due to the 
alterations in membrane permeability as reported by other 
workers in this pathophysiological condition. HMG was 
capable to counteract the effects produced by diabetogenic 
agent alloxan. In light of these observations and the 
current knowledge of the role of cAMP in regulating adipose 
tissue lipolysis, it is suggested that, like nicotinic acid, 
activity of HMG is mediated through its action on adenylate 
cyclase. In an independent study HMG has been shown to 
inhibit the activity of adenylate cyclase in triton-induced 
diabetic rats. Inhibitory effect of HMG on platelet 
aggregation seems to be a secondary effect produced as a 
result of the alterations of lipids and lipoproteins in 
i44 
plasma. Consequently this might affect the lipid composition 
of platelet membranes which is known to be directly 
influenced by the platelet environment, the blood plasma. 
All these effects are beneficial in the respect that they 
decrease the risk for coronary heart disease. 
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